Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Nuclear Medicine

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 782 articles:
HTML format



Single Articles


    May 2024
  1. LECY EE, Min HK, Apgar CJ, Maltais DD, et al
    Patterns of Early Neocortical Amyloid-beta Accumulation: A PET Population-Based Study.
    J Nucl Med. 2024 May 23:jnumed.123.267150. doi: 10.2967/jnumed.123.267150.
    PubMed     Abstract available


  2. IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al
    CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107.
    PubMed     Abstract available


  3. SMEETS EMM, Trajkovic-Arsic M, Geijs D, Karakaya S, et al
    Histology-Based Radiomics for [(18)F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.266262. doi: 10.2967/jnumed.123.266262.
    PubMed     Abstract available


  4. WATANABE M, Fendler WP, Grafe H, Hirmas N, et al
    Prognostic Implications of (68)Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.
    J Nucl Med. 2024 May 23:jnumed.123.266981. doi: 10.2967/jnumed.123.266981.
    PubMed     Abstract available


  5. SADAGHIANI MS, Baskaran S, Gorin MA, Rowe SP, et al
    Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.
    J Nucl Med. 2024 May 23:jnumed.124.267417. doi: 10.2967/jnumed.124.267417.
    PubMed     Abstract available


  6. HEIDARI P, Haj-Mirzaian A, Prabhu S, Ataeinia B, et al
    Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease.
    J Nucl Med. 2024 May 16:jnumed.123.267344. doi: 10.2967/jnumed.123.267344.
    PubMed     Abstract available


  7. YADAV S, Jiang F, Kurkowska S, Saelee R, et al
    Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
    J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208.
    PubMed     Abstract available


  8. CAOBELLI F, Gozlugol N, Bakula A, Rominger A, et al
    Prognostic Value of [(99m)Tc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function.
    J Nucl Med. 2024 May 9:jnumed.123.266926. doi: 10.2967/jnumed.123.266926.
    PubMed     Abstract available


  9. LANZAFAME H, Mavroeidi IA, Pabst KM, Desaulniers M, et al
    (68)Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.
    J Nucl Med. 2024 May 9:jnumed.123.267248. doi: 10.2967/jnumed.123.267248.
    PubMed     Abstract available


  10. MILLER RJH, Shanbhag A, Michalowska AM, Kavanagh P, et al
    Deep Learning-Enabled Quantification of (99m)Tc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis.
    J Nucl Med. 2024 May 9:jnumed.124.267542. doi: 10.2967/jnumed.124.267542.
    PubMed     Abstract available


  11. ZANG J, Yang Y, Chen S, Wang C, et al
    Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
    J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940.
    PubMed     Abstract available


  12. HOEK R, van Diemen PA, Raijmakers PG, Driessen RS, et al
    Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [(15)O]H(2)O PET Imaging.
    J Nucl Med. 2024 May 9:jnumed.123.267195. doi: 10.2967/jnumed.123.267195.
    PubMed     Abstract available


  13. WU Y, Sun T, Ng YL, Liu J, et al
    Clinical Implementation of Total-Body PET in China.
    J Nucl Med. 2024;65.
    PubMed     Abstract available


  14. ZHANG J, Duan X, Chen X, Zhang Z, et al
    Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with (68)Ga-N188.
    J Nucl Med. 2024;65.
    PubMed     Abstract available


  15. MENG X, Kong X, Xia L, Wu R, et al
    The Role of Total-Body PET in Drug Development and Evaluation: Status and Outlook.
    J Nucl Med. 2024;65.
    PubMed     Abstract available


  16. YANG W, Kang F, Chen Y, Zhu Z, et al
    Landscape of Nuclear Medicine in China and Its Progress on Theranostics.
    J Nucl Med. 2024;65.
    PubMed     Abstract available


  17. AN S, Wang L, Xie F, Jiang D, et al
    Pathway to Approval of Innovative Radiopharmaceuticals in China.
    J Nucl Med. 2024;65.
    PubMed     Abstract available


  18. CHEN H, Shi K, Cai W, Li S, et al
    Advancing Global Nuclear Medicine: The Role and Future Contributions of China.
    J Nucl Med. 2024;65.
    PubMed    


  19. ZHAO L, Kang F, Pang Y, Fang J, et al
    Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China.
    J Nucl Med. 2024;65.
    PubMed     Abstract available


  20. CHEN W, Li Y, Li Z, Jiang Y, et al
    Advantages and Challenges of Total-Body PET/CT at a Tertiary Cancer Center: Insights from Sun Yat-sen University Cancer Center.
    J Nucl Med. 2024;65.
    PubMed     Abstract available


  21. KLINE B, Yadav S, Seo Y, Ippisch RC, et al
    (68)Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with (18)F-FDG.
    J Nucl Med. 2024 May 2:jnumed.123.267281. doi: 10.2967/jnumed.123.267281.
    PubMed     Abstract available


  22. MA Y, Zeng J, Ding F, Xu Y, et al
    Cerebral (18)F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune Checkpoint Blockade Cancer Treatment.
    J Nucl Med. 2024 May 2:jnumed.123.267025. doi: 10.2967/jnumed.123.267025.
    PubMed     Abstract available


  23. FEHER A, Bednarski B, Miller RJ, Shanbhag A, et al
    Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging.
    J Nucl Med. 2024;65:768-774.
    PubMed     Abstract available



  24. Gerald L. DeNardo, MD, 1932-2024.
    J Nucl Med. 2024;65:823.
    PubMed    


    April 2024
  25. ROSEN J, Werner JM, Ceccon GS, Rosen EK, et al
    MRI and (18)F-FET PET for Multimodal Treatment Monitoring in Patients with Brain Metastases: A Cost-Effectiveness Analysis.
    J Nucl Med. 2024 Apr 25:jnumed.123.266687. doi: 10.2967/jnumed.123.266687.
    PubMed     Abstract available


  26. NIKITAS J, Lam E, Booker KA, Fendler WP, et al
    Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
    J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004.
    PubMed     Abstract available


  27. MINGELS C, Spencer BA, Nalbant H, Omidvari N, et al
    Dose Reduction in Pediatric Oncology Patients with Delayed Total-Body [(18)F]FDG PET/CT.
    J Nucl Med. 2024 Apr 25:jnumed.124.267521. doi: 10.2967/jnumed.124.267521.
    PubMed     Abstract available


  28. DUAN H, Song H, Davidzon GA, Moradi F, et al
    Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017.
    PubMed     Abstract available


  29. BURKETT BJ, Johnson DR, Lowe VJ
    Evaluation of Neurodegenerative Disorders with Amyloid-beta, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls.
    J Nucl Med. 2024 Apr 25:jnumed.123.266463. doi: 10.2967/jnumed.123.266463.
    PubMed     Abstract available


  30. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
    RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234.
    PubMed     Abstract available


  31. LEUBE J, Gustafsson J, Lassmann M, Salas-Ramirez M, et al
    A Deep-Learning-Based Partial-Volume Correction Method for Quantitative (177)Lu SPECT/CT Imaging.
    J Nucl Med. 2024 Apr 18:jnumed.123.266889. doi: 10.2967/jnumed.123.266889.
    PubMed     Abstract available


  32. HAGENS MJ, van Leeuwen PJ, Wondergem M, Boellaard TN, et al
    A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers.
    J Nucl Med. 2024 Apr 18:jnumed.123.267260. doi: 10.2967/jnumed.123.267260.
    PubMed     Abstract available


  33. MOSER R, Pfeiffer S, Cala L, Klein E, et al
    Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of (18)F-FDG PET/CT and Conventional CT Imaging.
    J Nucl Med. 2024 Apr 18:jnumed.123.266925. doi: 10.2967/jnumed.123.266925.
    PubMed     Abstract available


  34. SWIHA M, Papa N, Sabahi Z, Ayati N, et al
    Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes.
    J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
    PubMed     Abstract available


  35. QI C, Guo R, Chen Y, Li C, et al
    (68)Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients.
    J Nucl Med. 2024 Apr 11:jnumed.123.267110. doi: 10.2967/jnumed.123.267110.
    PubMed     Abstract available


  36. ROHRICH M, Daum J, Gutjahr E, Spektor AM, et al
    Diagnostic Potential of Supplemental Static and Dynamic (68)Ga-FAPI-46 PET for Primary (18)F-FDG-Negative Pulmonary Lesions.
    J Nucl Med. 2024 Apr 11:jnumed.123.267103. doi: 10.2967/jnumed.123.267103.
    PubMed     Abstract available


  37. O'DONNELL JL, Soda AK, Jiang H, Norris SA, et al
    PET Quantification of [(18)F]VAT in Human Brain and Its Test-Retest Reproducibility and Age Dependence.
    J Nucl Med. 2024 Apr 11:jnumed.123.266860. doi: 10.2967/jnumed.123.266860.
    PubMed     Abstract available


  38. VISCUSE P, Devitt M, Dreicer R
    Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
    J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
    PubMed     Abstract available


  39. WU Q, Gu F, O'Suilleabhain LD, Sari H, et al
    Mapping (18)F-FDG Kinetics Together with Patient-Specific Bootstrap Assessment of Uncertainties: An Illustration with Data from a PET/CT Scanner with a Long Axial Field of View.
    J Nucl Med. 2024 Apr 11:jnumed.123.266686. doi: 10.2967/jnumed.123.266686.
    PubMed     Abstract available


  40. BARATTO L, Singh SB, Williams SE, Spunt SL, et al
    Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [(18)F]FDG PET/MRI: A Pilot Study.
    J Nucl Med. 2024 Apr 4:jnumed.123.266760. doi: 10.2967/jnumed.123.266760.
    PubMed     Abstract available


  41. GEBHART G, Keyaerts M, Guiot T, Flamen P, et al
    Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
    J Nucl Med. 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384.
    PubMed     Abstract available


  42. BISCHOF GN, Brendel M, Barthel H, Theis H, et al
    Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [(18)F]PI-2620.
    J Nucl Med. 2024 Apr 4:jnumed.123.265930. doi: 10.2967/jnumed.123.265930.
    PubMed     Abstract available


  43. RUWANPATHIRANA GP, Williams RC, Masters CL, Rowe CC, et al
    Impact of PET Reconstruction on Amyloid-beta Quantitation in Cross-Sectional and Longitudinal Analyses.
    J Nucl Med. 2024 Apr 4:jnumed.123.266188. doi: 10.2967/jnumed.123.266188.
    PubMed     Abstract available


  44. SCHULER M, Hense J, Darwiche K, Michels S, et al
    Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
    J Nucl Med. 2024 Apr 4:jnumed.123.266979. doi: 10.2967/jnumed.123.266979.
    PubMed     Abstract available


  45. LI Z, Benabdallah N, Luo J, Wahl RL, et al
    ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner-Collimator Configurations for (223)Ra-Based Radiopharmaceutical Therapies.
    J Nucl Med. 2024 Apr 4:jnumed.123.266719. doi: 10.2967/jnumed.123.266719.
    PubMed     Abstract available


    March 2024
  46. ALTENA R, Buren SA, Blomgren A, Karlsson E, et al
    Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [(68)Ga]Ga-ABY-025: Results from a Pilot Study.
    J Nucl Med. 2024 Mar 28:jnumed.123.266847. doi: 10.2967/jnumed.123.266847.
    PubMed     Abstract available


  47. COLLARINO A, Feudo V, Pasciuto T, Florit A, et al
    Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer?
    J Nucl Med. 2024 Mar 28:jnumed.123.267044. doi: 10.2967/jnumed.123.267044.
    PubMed     Abstract available


  48. BLAKKISRUD J, Peterson AB, Wildermann SJ, Kingkiner G, et al
    SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [(177)Lu]Lu-DOTATATE.
    J Nucl Med. 2024 Mar 28:jnumed.123.266843. doi: 10.2967/jnumed.123.266843.
    PubMed     Abstract available


  49. ZHANG X, Heo GS, Li A, Lahad D, et al
    Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages in Atherosclerosis.
    J Nucl Med. 2024 Mar 28:jnumed.123.266910. doi: 10.2967/jnumed.123.266910.
    PubMed     Abstract available


  50. WANG Y, Abdelhafez YG, Spencer BA, Verma R, et al
    High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET.
    J Nucl Med. 2024 Mar 28:jnumed.123.267036. doi: 10.2967/jnumed.123.267036.
    PubMed     Abstract available


  51. HAIDER SP, Zeevi T, Sharaf K, Gross M, et al
    Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.
    J Nucl Med. 2024 Mar 21:jnumed.123.266637. doi: 10.2967/jnumed.123.266637.
    PubMed     Abstract available


  52. PRUIS IJ, Verburg FA, Balvers RK, Harteveld AA, et al
    [(18)F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors.
    J Nucl Med. 2024 Mar 21:jnumed.123.266853. doi: 10.2967/jnumed.123.266853.
    PubMed     Abstract available


  53. LIU N, Yang X, Gao C, Wang J, et al
    Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses.
    J Nucl Med. 2024 Mar 21:jnumed.123.266888. doi: 10.2967/jnumed.123.266888.
    PubMed     Abstract available


  54. JAGUST WJ, Mattay VS, Krainak DM, Wang SJ, et al
    Quantitative Brain Amyloid PET.
    J Nucl Med. 2024 Mar 21:jnumed.123.265766. doi: 10.2967/jnumed.123.265766.
    PubMed     Abstract available


  55. CYTRYN SL, Pandit-Taskar N, Lumish MA, Maron SB, et al
    (18)F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer.
    J Nucl Med. 2024 Mar 21:jnumed.123.267186. doi: 10.2967/jnumed.123.267186.
    PubMed     Abstract available


  56. SHI J, Li D, Chen M, Fu Y, et al
    The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
    J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
    PubMed     Abstract available


  57. BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al
    Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
    J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075.
    PubMed     Abstract available


  58. SAHIN E, Kus T, Aytekin A, Uzun E, et al
    (68)Ga-FAPI PET/CT as an Alternative to (18)F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.
    J Nucl Med. 2024 Mar 14:jnumed.123.266798. doi: 10.2967/jnumed.123.266798.
    PubMed     Abstract available


  59. PORTER JC, Ganeshan B, Win T, Fraioli F, et al
    [(18)F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases.
    J Nucl Med. 2024 Mar 14:jnumed.123.266445. doi: 10.2967/jnumed.123.266445.
    PubMed     Abstract available


  60. PROVIDENCIA L, van der Weijden CWJ, Mohr P, van Sluis J, et al
    Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies?
    J Nucl Med. 2024 Mar 14:jnumed.123.266675. doi: 10.2967/jnumed.123.266675.
    PubMed     Abstract available


  61. THOR M, Lee C, Sun L, Patel P, et al
    An (18)F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy.
    J Nucl Med. 2024 Mar 14:jnumed.123.266965. doi: 10.2967/jnumed.123.266965.
    PubMed     Abstract available


  62. DRESCHER R, Greiser J, Grober S, Weisheit T, et al
    (64)Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal Fluid Space.
    J Nucl Med. 2024 Mar 14:jnumed.123.267329. doi: 10.2967/jnumed.123.267329.
    PubMed    


  63. HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al
    Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
    J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702.
    PubMed     Abstract available


  64. LI C, Chen Q, Tian Y, Chen J, et al
    (68)Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression.
    J Nucl Med. 2024 Mar 7:jnumed.123.266806. doi: 10.2967/jnumed.123.266806.
    PubMed     Abstract available


  65. HOVHANNISYAN-BAGHDASARIAN N, Luporsi M, Captier N, Nioche C, et al
    Promising Candidate Prognostic Biomarkers in [(18)F]FDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients.
    J Nucl Med. 2024 Mar 7:jnumed.123.266331. doi: 10.2967/jnumed.123.266331.
    PubMed     Abstract available


  66. CUZZANI G, Fortunati E, Zanoni L, Nanni C, et al
    Case Report: Pulmonary Actinomyces Infection Mimics Lung Cancer on [(68)Ga]Ga-FAPI PET/CT.
    J Nucl Med. 2024 Mar 7:jnumed.123.267155. doi: 10.2967/jnumed.123.267155.
    PubMed    


  67. FAROLFI A, Armstrong WR, Djaileb L, Gafita A, et al
    Differences and Common Ground in (177)Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
    J Nucl Med. 2024;65:438-445.
    PubMed     Abstract available


    February 2024
  68. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    PubMed     Abstract available


  69. JIANG M, Tang S, Jenkins MD, Lee AC, et al
    Robust Quantification of Phosphodiesterase-4D in Monkey Brain with PET and (11)C-Labeled Radioligands That Avoid Radiometabolite Contamination.
    J Nucl Med. 2024 Feb 29:jnumed.123.266750. doi: 10.2967/jnumed.123.266750.
    PubMed     Abstract available


  70. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
    First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.
    PubMed    


  71. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
    The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
    PubMed     Abstract available


  72. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
    Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
    PubMed     Abstract available


  73. KOVACS DG, Ladefoged CN, Andersen KF, Brittain JM, et al
    Clinical Evaluation of Deep Learning for Tumor Delineation on (18)F-FDG PET/CT of Head and Neck Cancer.
    J Nucl Med. 2024 Feb 22:jnumed.123.266574. doi: 10.2967/jnumed.123.266574.
    PubMed     Abstract available


  74. LI G, Ma W, Li X, Yang W, et al
    Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard.
    J Nucl Med. 2024 Feb 22:jnumed.123.265929. doi: 10.2967/jnumed.123.265929.
    PubMed     Abstract available


  75. SLART RHJA, Bengel FM, Akincioglu C, Bourque JM, et al
    Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council.
    J Nucl Med. 2024 Feb 22:jnumed.123.266858. doi: 10.2967/jnumed.123.266858.
    PubMed     Abstract available


  76. BOURBONNE V, Morjani M, Pradier O, Hatt M, et al
    PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy.
    J Nucl Med. 2024 Feb 15:jnumed.123.266749. doi: 10.2967/jnumed.123.266749.
    PubMed     Abstract available


  77. LOHMANN P, Gutsche R, Werner JM, Shah NJ, et al
    Example of Artificial Intelligence-Based Decision Support for Amino Acid PET: Early Prediction of Suspected Brain Tumor Foci for Patient Management.
    J Nucl Med. 2024 Feb 15:jnumed.123.267112. doi: 10.2967/jnumed.123.267112.
    PubMed    


  78. DRAKE LR, Wu Y, Naganawa M, Asch R, et al
    First-in-Human Study of (18)F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding.
    J Nucl Med. 2024 Feb 15:jnumed.123.266470. doi: 10.2967/jnumed.123.266470.
    PubMed     Abstract available


  79. LIU Z, Mhlanga JC, Xia H, Siegel BA, et al
    Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial Data.
    J Nucl Med. 2024 Feb 15:jnumed.123.266018. doi: 10.2967/jnumed.123.266018.
    PubMed     Abstract available


  80. KISHAN AU, Siva S, Hofman MS, Nagarajah J, et al
    The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease.
    J Nucl Med. 2024 Feb 15:jnumed.123.266772. doi: 10.2967/jnumed.123.266772.
    PubMed     Abstract available


  81. DUBASH S, Barwick TD, Kozlowski K, Rockall AG, et al
    Somatostatin Receptor Imaging with [(18)F]FET-betaAG-TOCA PET/CT and [(68)Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.
    J Nucl Med. 2024 Feb 8:jnumed.123.266601. doi: 10.2967/jnumed.123.266601.
    PubMed     Abstract available


  82. HIRMAS N, Hamacher R, Sraieb M, Kessler L, et al
    Diagnostic Accuracy of (68)Ga-FAPI Versus (18)F-FDG PET in Patients with Various Malignancies.
    J Nucl Med. 2024 Feb 8:jnumed.123.266652. doi: 10.2967/jnumed.123.266652.
    PubMed     Abstract available


  83. GONDRY O, Caveliers V, Xavier C, Raes L, et al
    Phase II Trial Assessing the Repeatability and Tumor Uptake of [(68)Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
    J Nucl Med. 2024;65:178-184.
    PubMed     Abstract available


  84. OH M, Oh SJ, Lee SJ, Oh JS, et al
    One-Year Longitudinal Changes in Tau Accumulation on [(18)F]PI-2620 PET in the Alzheimer Spectrum.
    J Nucl Med. 2024 Feb 1:jnumed.123.265893. doi: 10.2967/jnumed.123.265893.
    PubMed     Abstract available


  85. SOULEN MC, Rilling WS
    Clinical Outcomes After Personalized Dosimetry for (90)Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape.
    J Nucl Med. 2024;65:270-271.
    PubMed    


  86. AL MANSOUR L, De Mestier L, Haissaguerre M, Afchain P, et al
    Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Networ
    J Nucl Med. 2024;65:258-263.
    PubMed     Abstract available


  87. HAMACHER R, Pabst KM, Cheung PF, Heilig CE, et al
    Fibroblast Activation Protein alpha-Directed Imaging and Therapy of Solitary Fibrous Tumor.
    J Nucl Med. 2024;65:252-257.
    PubMed     Abstract available


  88. WAGEMANS MEHM, Kunnen B, Stella M, van Rooij R, et al
    Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
    J Nucl Med. 2024;65:272-278.
    PubMed     Abstract available


  89. HE Y, Kramer SD, Grether U, Wittwer MB, et al
    Identification of (R)-[(18)F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development.
    J Nucl Med. 2024;65:300-305.
    PubMed     Abstract available


  90. MILEVA M, Marin G, Levillain H, Artigas C, et al
    Prediction of (177)Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.
    J Nucl Med. 2024;65:236-244.
    PubMed     Abstract available


  91. GIRUM KB, Cottereau AS, Vercellino L, Rebaud L, et al
    Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
    J Nucl Med. 2024;65:313-319.
    PubMed     Abstract available


  92. CHIESA C, Bagnalasta M, Maccauro M
    Good Voxel Dosimetry with a Simplified Study Design Resulted in Improvable Safety Limits.
    J Nucl Med. 2024;65:331-332.
    PubMed    


    January 2024
  93. GU B, Yang Z, Du X, Xu X, et al
    Imaging of Tumor Stroma Using (68)Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
    J Nucl Med. 2024 Jan 25:jnumed.123.266556. doi: 10.2967/jnumed.123.266556.
    PubMed     Abstract available


  94. KIRBY A, Graf D, Suchy M, Calvert ND, et al
    It's a Trap! Aldolase-Prescribed C(4) Deoxyradiofluorination Affords Intracellular Trapping and the Tracing of Fructose Metabolism by PET.
    J Nucl Med. 2024 Jan 25:jnumed.123.266905. doi: 10.2967/jnumed.123.266905.
    PubMed     Abstract available


  95. YEH R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al
    First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
    J Nucl Med. 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.
    PubMed     Abstract available


  96. BUCHERT R, Szabo B, Kovacs A, Buddenkotte T, et al
    Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole Collimators.
    J Nucl Med. 2024 Jan 18:jnumed.123.266276. doi: 10.2967/jnumed.123.266276.
    PubMed     Abstract available


  97. LIGHT A, Lazic S, Houghton K, Bayne M, et al
    Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527.
    PubMed     Abstract available


  98. BARLATEY SL, Mignardot CG, Friedrichs-Maeder C, Schindler K, et al
    Triggered Seizures for Ictal SPECT Imaging: A Case Series and Feasibility Study.
    J Nucl Med. 2024 Jan 11:jnumed.123.266515. doi: 10.2967/jnumed.123.266515.
    PubMed     Abstract available


  99. KOSHKIN VS, Kumar V, Kline B, Escobar D, et al
    Initial Experience with (68)Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266390. doi: 10.2967/jnumed.123.266390.
    PubMed     Abstract available


  100. UNTERRAINER LM, Memarzadeh S, Moatamed NA, Benz MR, et al
    [(68)Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor.
    J Nucl Med. 2024 Jan 11:jnumed.123.266732. doi: 10.2967/jnumed.123.266732.
    PubMed    


  101. HOPE TA, Jadvar H
    PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3.
    J Nucl Med. 2024 Jan 4:jnumed.123.267042. doi: 10.2967/jnumed.123.267042.
    PubMed    


  102. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
    PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
    J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
    PubMed    


  103. DE WINTER RW, van Diemen PA, Schumacher SP, Jukema RA, et al
    Hemodynamic Insights into Combined Fractional Flow Reserve and Instantaneous Wave-Free Ratio Assessment Through Quantitative [(15)O]H(2)O PET Myocardial Perfusion Imaging.
    J Nucl Med. 2024 Jan 4:jnumed.123.265973. doi: 10.2967/jnumed.123.265973.
    PubMed     Abstract available


  104. RAHBAR K, Boegemann M
    The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
    J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.
    PubMed    


  105. LI X, Lu N, Lin L, Chen Y, et al
    (18)F-FAPI-04 Outperforms (18)F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma.
    J Nucl Med. 2024 Jan 4:jnumed.123.266283. doi: 10.2967/jnumed.123.266283.
    PubMed     Abstract available


  106. ZHAO L, Pang Y, Fang J, Chen J, et al
    Design, Preclinical Evaluation, and Clinical Translation of (68)Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
    J Nucl Med. 2024 Jan 4:jnumed.123.266183. doi: 10.2967/jnumed.123.266183.
    PubMed     Abstract available


  107. STRUNK M, Heo GS, Hess A, Luehmann H, et al
    Toward Quantitative Multisite Preclinical Imaging Studies in Acute Myocardial Infarction: Evaluation of the Immune-Fibrosis Axis.
    J Nucl Med. 2024 Jan 4:jnumed.123.266526. doi: 10.2967/jnumed.123.266526.
    PubMed     Abstract available


  108. SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al
    Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
    J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495.
    PubMed     Abstract available


  109. SPEKTOR AM, Gutjahr E, Lang M, Glatting FM, et al
    Immunohistochemical FAP Expression Reflects (68)Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma.
    J Nucl Med. 2024;65:52-58.
    PubMed     Abstract available


  110. PAPPAS V, Czernin J
    Expanding the Mission and Influence of SNMMI: A Conversation Between Johannes Czernin and Virginia Pappas About Her Career in SNMMI Leadership.
    J Nucl Med. 2024;65:1-3.
    PubMed    


  111. POPLAWSKI SE, Hallett RM, Dornan MH, Novakowski KE, et al
    Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-alpha (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
    J Nucl Med. 2024;65:100-108.
    PubMed     Abstract available


  112. MALIHA PG, Hotta M, Czernin J, Calais J, et al
    Characterizing Normal Variant [(68)Ga]Ga-FAPI-46 Uptake in the Epididymis.
    J Nucl Med. 2024;65:59-62.
    PubMed     Abstract available


  113. LUTHRIA G, Baratto L, Adams L, Morakote W, et al
    Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology Patients After Coronavirus Disease 2019 Vaccination.
    J Nucl Med. 2024;65:22-24.
    PubMed     Abstract available


  114. ENKE JS, Reitsam NG, Grosser B, Kircher M, et al
    C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy of Multiple Myeloma Using [(99m)Tc]Tc-PentixaTec.
    J Nucl Med. 2024;65:163-164.
    PubMed    


    December 2023
  115. CHAN DL, Hayes AR, Karfis I, Conner A, et al
    [(18)F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study.
    J Nucl Med. 2023 Dec 21:jnumed.123.266346. doi: 10.2967/jnumed.123.266346.
    PubMed     Abstract available


  116. MIAO Y, Feng R, Yu T, Guo R, et al
    Value of (68)Ga-FAPI-04 and (18)F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
    J Nucl Med. 2023 Dec 21:jnumed.123.266403. doi: 10.2967/jnumed.123.266403.
    PubMed     Abstract available


  117. VENTURA D, Dittmann M, Buther F, Schafers M, et al
    Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
    J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
    PubMed     Abstract available


  118. DIERKS A, Gable A, Rinscheid A, Wienand G, et al
    First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
    J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741.
    PubMed     Abstract available


  119. BARTLETT EA, Lesanpezeshki M, Anishchenko S, Shkolnik I, et al
    Dynamic Human Brain Imaging with a Portable PET Camera: Comparison to a Standard Scanner.
    J Nucl Med. 2023 Dec 14:jnumed.122.265309. doi: 10.2967/jnumed.122.265309.
    PubMed     Abstract available


  120. FETTAHOGLU A, Zhao M, Khalighi M, Vossler H, et al
    Early-Frame [(18)F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in Patients with Cognitive Impairment: Comparison to an [(15)O]Water Gold Standard.
    J Nucl Med. 2023 Dec 7:jnumed.123.266273. doi: 10.2967/jnumed.123.266273.
    PubMed     Abstract available


  121. MANKOFF D, Balogova S, Dunnwald L, Dehdashti F, et al
    Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16alpha-[(18)F]Fluoro-17beta-Estradiol PET.
    J Nucl Med. 2023 Dec 7:jnumed.123.266938. doi: 10.2967/jnumed.123.266938.
    PubMed     Abstract available


  122. NADEL HR
    A Strategic Approach to Advancing Nuclear Medicine and Molecular Imaging.
    J Nucl Med. 2023;64:1843-1844.
    PubMed    


  123. BLAZHENETS G, Soleimani-Meigooni DN, Thomas W, Mundada N, et al
    [(18)F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration.
    J Nucl Med. 2023;64:1980-1989.
    PubMed     Abstract available


  124. FANI M, Nicolas GP
    (61)Cu-Labeled Radiotracers: Alternative or Choice?
    J Nucl Med. 2023;64:1855-1857.
    PubMed    


    November 2023
  125. EMMETT L, Papa N, Counter W, Calais J, et al
    Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
    J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164.
    PubMed     Abstract available


  126. WANG F, Liu C, Vidal I, Mana-Ay M, et al
    Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT.
    J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005.
    PubMed     Abstract available


  127. DING J, Li X, Liu S, Gao Y, et al
    Clinical Value of (68)Ga-Pentixafor PET/CT in Subtype Diagnosis of Primary Aldosteronism Patients with Adrenal Micronodules.
    J Nucl Med. 2023 Nov 30:jnumed.123.266061. doi: 10.2967/jnumed.123.266061.
    PubMed     Abstract available


  128. KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al
    Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
    J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158.
    PubMed     Abstract available


  129. PUUVUORI E, Shen Y, Hulsart-Billstrom G, Mitran B, et al
    Noninvasive PET Detection of CD69-Positive Immune Cells Before Signs of Clinical Disease in Inflammatory Arthritis.
    J Nucl Med. 2023 Nov 30:jnumed.123.266336. doi: 10.2967/jnumed.123.266336.
    PubMed     Abstract available


  130. NDLOVU H, Lawal I, Mokoala K, Disenyane D, et al
    Imaging PARP Upregulation with [(123)I]I-PARPi SPECT/CT in Small Cell Neuroendocrine Carcinoma.
    J Nucl Med. 2023 Nov 30:jnumed.123.266348. doi: 10.2967/jnumed.123.266348.
    PubMed    


  131. DOERING E, Antonopoulos G, Hoenig M, van Eimeren T, et al
    MRI or (18)F-FDG PET for Brain Age Gap Estimation: Links to Cognition, Pathology, and Alzheimer Disease Progression.
    J Nucl Med. 2023 Nov 30:jnumed.123.265931. doi: 10.2967/jnumed.123.265931.
    PubMed     Abstract available


  132. KURONUMA K, Wei CC, Singh A, Lemley M, et al
    Automated Motion Correction for Myocardial Blood Flow Measurements and Diagnostic Performance of (82)Rb PET Myocardial Perfusion Imaging.
    J Nucl Med. 2023 Nov 30:jnumed.123.266208. doi: 10.2967/jnumed.123.266208.
    PubMed     Abstract available


  133. QUAN Z, Han Z, Yang Y, Wang J, et al
    Noninvasive Monitoring of Immunotherapy in Lung Cancer by Lymphocyte Activation Gene 3 PET Imaging of Tumor-Infiltrating Lymphocytes.
    J Nucl Med. 2023 Nov 16:jnumed.123.266002. doi: 10.2967/jnumed.123.266002.
    PubMed     Abstract available


  134. KESSLER L, Hirmas N, Pabst KM, Hamacher R, et al
    (68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial.
    J Nucl Med. 2023 Nov 16:jnumed.122.264827. doi: 10.2967/jnumed.122.264827.
    PubMed     Abstract available


  135. NAMMAS W, Paunonen C, Teuho J, Siekkinen R, et al
    Imaging of Myocardial alpha(v)beta(3) Integrin Expression for Evaluation of Myocardial Injury After Acute Myocardial Infarction.
    J Nucl Med. 2023 Nov 16:jnumed.123.266148. doi: 10.2967/jnumed.123.266148.
    PubMed     Abstract available


  136. BALAJI V, Song TA, Malekzadeh M, Heidari P, et al
    Artificial Intelligence for PET and SPECT Image Enhancement.
    J Nucl Med. 2023 Nov 9:jnumed.122.265000. doi: 10.2967/jnumed.122.265000.
    PubMed     Abstract available


  137. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
    Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
    J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
    PubMed     Abstract available


  138. CARLIER T, Frecon G, Mateus D, Rizkallah M, et al
    Prognostic Value of (18)F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study.
    J Nucl Med. 2023 Nov 9:jnumed.123.265872. doi: 10.2967/jnumed.123.265872.
    PubMed     Abstract available


  139. CHEN L, Zheng S, Chen L, Xu S, et al
    (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.
    J Nucl Med. 2023 Nov 2:jnumed.123.266079. doi: 10.2967/jnumed.123.266079.
    PubMed     Abstract available


  140. REZAZADEH F, Kilcline AP, Viola NT
    Imaging Agents for PET of Inflammatory Bowel Disease: A Review.
    J Nucl Med. 2023 Nov 2:jnumed.123.265935. doi: 10.2967/jnumed.123.265935.
    PubMed     Abstract available


  141. VIERING O, Gunther T, Holzleitner N, Dierks A, et al
    CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [(68)Ga]Ga-DOTA-CCK-66.
    J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380.
    PubMed    


  142. GEBHART G
    (18)F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast Cancer: Quo Vadis?
    J Nucl Med. 2023;64:1697-1698.
    PubMed    


  143. KNUUTI J, Tuisku J, Karpijoki H, Iida H, et al
    Quantitative Perfusion Imaging with Total-Body PET.
    J Nucl Med. 2023;64.
    PubMed     Abstract available


  144. DI CARLI MF
    Future of Radionuclide Myocardial Perfusion Imaging: Transitioning from SPECT to PET.
    J Nucl Med. 2023;64.
    PubMed    


  145. BENGEL FM, Di Carli MF
    The Evolution of Cardiac Nuclear Imaging.
    J Nucl Med. 2023;64.
    PubMed    


  146. ROLL W, Faust A, Hermann S, Schafers M, et al
    Infection Imaging: Focus on New Tracers?
    J Nucl Med. 2023;64.
    PubMed     Abstract available


  147. LI EJ, Lopez JE, Spencer BA, Abdelhafez Y, et al
    Total-Body Perfusion Imaging with [(11)C]-Butanol.
    J Nucl Med. 2023;64:1831-1838.
    PubMed     Abstract available


    October 2023
  148. KAYAL G, Barbosa N, Calderon Marin C, Ferrer L, et al
    Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study.
    J Nucl Med. 2023 Oct 26:jnumed.122.265340. doi: 10.2967/jnumed.122.265340.
    PubMed     Abstract available


  149. MAULER J, Lohmann P, Maudsley AA, Sheriff S, et al
    Diagnostic Accuracy of MR Spectroscopic Imaging and (18)F-FET PET for Identifying Glioma: A Biopsy-Controlled Hybrid PET/MRI Study.
    J Nucl Med. 2023 Oct 26:jnumed.123.265868. doi: 10.2967/jnumed.123.265868.
    PubMed     Abstract available


  150. XU W, Cai J, Peng T, Meng T, et al
    Fibroblast Activation Protein-Targeted PET/CT with (18)F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with (18)F-FDG PET/CT.
    J Nucl Med. 2023 Oct 26:jnumed.123.266329. doi: 10.2967/jnumed.123.266329.
    PubMed     Abstract available


  151. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
    Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
    J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
    PubMed     Abstract available


  152. KAIREMO K, Czernin J
    Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin Discusses Innovation and Translation with Kalevi Kairemo.
    J Nucl Med. 2023 Oct 19:jnumed.123.266793. doi: 10.2967/jnumed.123.266793.
    PubMed    


  153. YAMAGISHI S, Miwa K, Kamitaki S, Anraku K, et al
    Performance Characteristics of a New-Generation Digital Bismuth Germanium Oxide PET/CT System, Omni Legend 32, According to NEMA NU 2-2018 Standards.
    J Nucl Med. 2023 Oct 19:jnumed.123.266140. doi: 10.2967/jnumed.123.266140.
    PubMed     Abstract available


  154. LI X, Ye J, Wang J, Quan Z, et al
    First-in-Humans PET Imaging of KRAS(G12C) Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [(18)F]PFPMD.
    J Nucl Med. 2023 Oct 12:jnumed.123.265715. doi: 10.2967/jnumed.123.265715.
    PubMed     Abstract available


  155. WATABE T, Kabayama K, Naka S, Yamamoto R, et al
    Immuno-PET and Targeted alpha-Therapy Using Anti-Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.
    J Nucl Med. 2023 Oct 12:jnumed.123.266313. doi: 10.2967/jnumed.123.266313.
    PubMed     Abstract available


  156. AL-TOUBAH T, Montilla-Soler J, El-Haddad G, Haider M, et al
    Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.
    J Nucl Med. 2023 Oct 5:jnumed.123.266185. doi: 10.2967/jnumed.123.266185.
    PubMed     Abstract available


  157. DUELL J, Buck AK, Hartrampf PE, Schlotelburg W, et al
    Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.
    J Nucl Med. 2023 Oct 5:jnumed.123.266074. doi: 10.2967/jnumed.123.266074.
    PubMed     Abstract available


  158. SCHEUERMANN JS, Pryma DA
    Choosing the Right Metrics for Evaluation of Radiopharmaceutical Therapy Dosimetry Methodologies.
    J Nucl Med. 2023;64:1617-1618.
    PubMed    


  159. CHICHEPORTICHE A, Sason M, Zidan M, Godefroy J, et al
    Impact of Single-Time-Point Estimates of (177)Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles.
    J Nucl Med. 2023;64:1610-1616.
    PubMed     Abstract available


  160. GANZ PA, Czernin J
    Pioneering Research on Cancer Quality of Life and Outcomes: Johannes Czernin Discusses a Half-Century of Whole-Patient Focus with Patricia A. Ganz.
    J Nucl Med. 2023;64:1506-1508.
    PubMed    


  161. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
    Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
    J Nucl Med. 2023;64:1632-1637.
    PubMed     Abstract available


  162. KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al
    Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
    J Nucl Med. 2023;64:1654-1659.
    PubMed     Abstract available


  163. COOK BE, Nag S, Arakawa R, Lin EY, et al
    Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain.
    J Nucl Med. 2023;64:1588-1593.
    PubMed     Abstract available


  164. HERINGTON J, McCradden MD, Creel K, Boellaard R, et al
    Ethical Considerations for Artificial Intelligence in Medical Imaging: Deployment and Governance.
    J Nucl Med. 2023;64:1509-1515.
    PubMed     Abstract available


    September 2023
  165. SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al
    PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
    J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874.
    PubMed     Abstract available


  166. HABERBOSCH L, Gillett D, MacFarlane J, Koulouri O, et al
    Dual Role for l-[Methyl-(11)C]-Methionine PET in Acromegaly: Confirming Remission and Detecting Recurrence.
    J Nucl Med. 2023 Sep 28:jnumed.123.266446. doi: 10.2967/jnumed.123.266446.
    PubMed    


  167. CONSTANTINESCU CC, Brown T, Wang S, Yin W, et al
    Clinical Characterization of [(18)F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy.
    J Nucl Med. 2023 Sep 28:jnumed.123.265912. doi: 10.2967/jnumed.123.265912.
    PubMed     Abstract available


  168. ALBERTO S, Ordonez AA, Arjun C, Aulakh GK, et al
    The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection.
    J Nucl Med. 2023 Sep 28:jnumed.123.265906. doi: 10.2967/jnumed.123.265906.
    PubMed     Abstract available


  169. CHAN CY, Chen Z, Guibbal F, Dias G, et al
    [(123)I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer.
    J Nucl Med. 2023 Sep 28:jnumed.123.265429. doi: 10.2967/jnumed.123.265429.
    PubMed     Abstract available


  170. SCHMIDKONZ C, Atzinger A, Ramming A, Kuwert T, et al
    FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders.
    J Nucl Med. 2023 Sep 21:jnumed.123.266182. doi: 10.2967/jnumed.123.266182.
    PubMed    


  171. KLUGE K, Haberl D, Einspieler H, Rasul S, et al
    Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
    J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980.
    PubMed     Abstract available


  172. ITTI E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, et al
    Validation of the DeltaSUV(max) for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.
    J Nucl Med. 2023 Sep 21:jnumed.123.265871. doi: 10.2967/jnumed.123.265871.
    PubMed     Abstract available


  173. DEMMERT TT, Pomykala KL, Lanzafame H, Pabst KM, et al
    Oncologic Staging with (68)Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than (18)F-FDG PET/CT.
    J Nucl Med. 2023 Sep 21:jnumed.123.265751. doi: 10.2967/jnumed.123.265751.
    PubMed     Abstract available


  174. ROGASCH JMM, Metzger G, Preisler M, Galler M, et al
    ChatGPT: Can You Prepare My Patients for [(18)F]FDG PET/CT and Explain My Reports?
    J Nucl Med. 2023 Sep 14:jnumed.123.266114. doi: 10.2967/jnumed.123.266114.
    PubMed     Abstract available


  175. ALTENA R, Af Buren S, Tran T, Axelsson R, et al
    HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266101. doi: 10.2967/jnumed.123.266101.
    PubMed    


  176. SEBAN RD
    Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266490. doi: 10.2967/jnumed.123.266490.
    PubMed    


  177. GEORGOULIAS P, Angelidis G, Koukouraki S, Koutsikos J, et al
    Debating the Future of Nuclear Medicine: The Greek Experience.
    J Nucl Med. 2023 Sep 14:jnumed.123.266646. doi: 10.2967/jnumed.123.266646.
    PubMed    


  178. GOGOLA A, Lopresti BJ, Tudorascu D, Snitz B, et al
    Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies.
    J Nucl Med. 2023 Sep 14:jnumed.123.265941. doi: 10.2967/jnumed.123.265941.
    PubMed    


  179. KOERBER SA, Rohrich M, Walkenbach L, Liermann J, et al
    Impact of (68)Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
    J Nucl Med. 2023 Sep 7:jnumed.123.266046. doi: 10.2967/jnumed.123.266046.
    PubMed     Abstract available


  180. MURTHY V, Gafita A, Thin P, Nguyen K, et al
    Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with (177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
    J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155.
    PubMed     Abstract available


  181. SUNDERLAND JJ, Graves SA, York DM, Mundt CA, et al
    Response to "Critique and Discussion of 'Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose'".
    J Nucl Med. 2023 Sep 7:jnumed.123.266596. doi: 10.2967/jnumed.123.266596.
    PubMed    


  182. KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al
    Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
    J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878.
    PubMed     Abstract available


  183. MANKOFF D
    The Future of Nuclear Medicine.
    J Nucl Med. 2023;64:1329-1330.
    PubMed    


  184. KRAEBER-BODERE F, Jamet B, Bezzi D, Zamagni E, et al
    New Developments in Myeloma Treatment and Response Assessment.
    J Nucl Med. 2023;64:1331-1343.
    PubMed     Abstract available


  185. WANG C, Peterson AB, Wong KK, Roseland ME, et al
    Single-Time-Point Imaging for Dosimetry After [(177)Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection.
    J Nucl Med. 2023;64:1463-1470.
    PubMed     Abstract available


  186. HARTLAPP I, Hartrampf PE, Serfling SE, Wild V, et al
    CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.
    J Nucl Med. 2023;64:1424-1430.
    PubMed     Abstract available


  187. PANG Y, Zhao L, Fang J, Chen J, et al
    Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    J Nucl Med. 2023;64:1449-1455.
    PubMed     Abstract available


  188. AHMAD AA, Ghim M, Toczek J, Neishabouri A, et al
    Multimodality Imaging of Aortic Valve Calcification and Function in a Murine Model of Calcific Aortic Valve Disease and Bicuspid Aortic Valve.
    J Nucl Med. 2023;64:1487-1494.
    PubMed     Abstract available


    August 2023
  189. DE RYCKE O, Perrier M, Ouvrard E, Mennetrey C, et al
    High Tumor Uptake on (18)F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d'etude des Tumeurs Endocrines and ENDOCAN-RENATEN Network.
    J Nucl Med. 2023 Aug 31:jnumed.123.265584. doi: 10.2967/jnumed.123.265584.
    PubMed     Abstract available


  190. HOHBERG M, Reifegerst M, Drzezga A, Wild M, et al
    Prediction of Response to (177)Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC.
    J Nucl Med. 2023 Aug 31:jnumed.122.264953. doi: 10.2967/jnumed.122.264953.
    PubMed     Abstract available


  191. ZHANG J, Kang F, Gao J, Jiao J, et al
    A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study.
    J Nucl Med. 2023 Aug 31:jnumed.122.265001. doi: 10.2967/jnumed.122.265001.
    PubMed     Abstract available


  192. LOHMEIER J, Radbruch H, Brenner W, Hamm B, et al
    Predictive IDH Genotyping Based on the Evaluation of Spatial Metabolic Heterogeneity by Compartmental Uptake Characteristics in Preoperative Glioma Using (18)F-FET PET.
    J Nucl Med. 2023 Aug 31:jnumed.123.265642. doi: 10.2967/jnumed.123.265642.
    PubMed     Abstract available


  193. GRKOVSKI M, O'Donoghue JA, Imber BS, Andl G, et al
    Lesion Dosimetry for [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.
    J Nucl Med. 2023 Aug 31:jnumed.123.265763. doi: 10.2967/jnumed.123.265763.
    PubMed     Abstract available


  194. VAN LITH SAM, Pruis IJ, Tolboom N, Snijders TJ, et al
    PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.
    J Nucl Med. 2023 Aug 31:jnumed.123.265738. doi: 10.2967/jnumed.123.265738.
    PubMed     Abstract available


  195. HENNESSY MA, Leal JP, Huang CY, Solnes LB, et al
    Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
    J Nucl Med. 2023 Aug 31:jnumed.123.265853. doi: 10.2967/jnumed.123.265853.
    PubMed     Abstract available


  196. ALAN-SELCUK N, Beydagi G, Demirci E, Ocak M, et al
    Clinical Experience with [(225)Ac]Ac-PSMA Treatment in Patients with [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2023 Aug 24:jnumed.123.265546. doi: 10.2967/jnumed.123.265546.
    PubMed     Abstract available


  197. HOPE TA, Benz M, Jiang F, Thompson D, et al
    Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.
    J Nucl Med. 2023 Aug 17:jnumed.123.265916. doi: 10.2967/jnumed.123.265916.
    PubMed     Abstract available


  198. BERTOGLIO D, Weiss AR, Liguore W, Martin LD, et al
    In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using (11)C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease.
    J Nucl Med. 2023 Aug 17:jnumed.123.265569. doi: 10.2967/jnumed.123.265569.
    PubMed     Abstract available


  199. BOLCAEN J, Gizawy MA, Terry SYA, Paulo A, et al
    Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy.
    J Nucl Med. 2023 Aug 17:jnumed.122.265039. doi: 10.2967/jnumed.122.265039.
    PubMed     Abstract available


  200. WANG Y, Nardo L, Spencer BA, Abdelhafez YG, et al
    Total-Body Multiparametric PET Quantification of (18)F-FDG Delivery and Metabolism in the Study of Coronavirus Disease 2019 Recovery.
    J Nucl Med. 2023 Aug 17:jnumed.123.265723. doi: 10.2967/jnumed.123.265723.
    PubMed     Abstract available


  201. EIFER M, Alipour R, Hofman MS, Ravi Kumar AS, et al
    Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?
    J Nucl Med. 2023 Aug 17:jnumed.123.266025. doi: 10.2967/jnumed.123.266025.
    PubMed    


  202. SEGALL GM, Watts M, Frey KA
    The Future of Nuclear Medicine in the United States.
    J Nucl Med. 2023 Aug 10:jnumed.123.265674. doi: 10.2967/jnumed.123.265674.
    PubMed    


  203. GRAHAM MM
    The Future of Nuclear Medicine in the United States.
    J Nucl Med. 2023 Aug 10:jnumed.122.265314. doi: 10.2967/jnumed.122.265314.
    PubMed     Abstract available


  204. CZERNIN J, Calais J
    Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States.
    J Nucl Med. 2023 Aug 10:jnumed.123.265672. doi: 10.2967/jnumed.123.265672.
    PubMed    


  205. GUTSCHE R, Lowis C, Ziemons K, Kocher M, et al
    Automated Brain Tumor Detection and Segmentation for Treatment Response Assessment Using Amino Acid PET.
    J Nucl Med. 2023 Aug 10:jnumed.123.265725. doi: 10.2967/jnumed.123.265725.
    PubMed     Abstract available


  206. MOHR P, van Sluis J, Providencia L, van Snick JH, et al
    Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for (89)Zr-Trastuzumab.
    J Nucl Med. 2023 Aug 3:jnumed.123.265621. doi: 10.2967/jnumed.123.265621.
    PubMed     Abstract available


  207. DE JONG AC, Segbers M, Ling SW, Graven LH, et al
    (68)Ga-PSMA PET/CT for Response Evaluation of (223)Ra Treatment in Metastatic Prostate Cancer.
    J Nucl Med. 2023 Aug 3:jnumed.123.265489. doi: 10.2967/jnumed.123.265489.
    PubMed     Abstract available


  208. ALBERT NL, Nelwan DV, Fleischmann DF, Quach S, et al
    Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type Glioblastoma.
    J Nucl Med. 2023 Aug 3:jnumed.122.265247. doi: 10.2967/jnumed.122.265247.
    PubMed     Abstract available


  209. PANIKAR SS, Keltee N, Berry NK, Shmuel S, et al
    Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors.
    J Nucl Med. 2023;64:1195-1202.
    PubMed     Abstract available


  210. ZHAO L, Wen X, Xu W, Pang Y, et al
    Clinical Evaluation of (68)Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin alpha(v)beta(3) in Various Cancer Types.
    J Nucl Med. 2023;64:1210-1217.
    PubMed     Abstract available


    July 2023
  211. WU M, Wang Y, Yang Q, Wang X, et al
    Comparison of Baseline (68)Ga-FAPI and (18)F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib.
    J Nucl Med. 2023 Jul 27:jnumed.123.265712. doi: 10.2967/jnumed.123.265712.
    PubMed     Abstract available


  212. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
    Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
    J Nucl Med. 2023 Jul 27:jnumed.123.265523. doi: 10.2967/jnumed.123.265523.
    PubMed     Abstract available


  213. ZHAO S, Wang J, Jin C, Zhang X, et al
    Stacking Ensemble Learning-Based [(18)F]FDG PET Radiomics for Outcome Prediction in Diffuse Large B-Cell Lymphoma.
    J Nucl Med. 2023 Jul 27:jnumed.122.265244. doi: 10.2967/jnumed.122.265244.
    PubMed     Abstract available


  214. KERSTING D, Sandach P, Sraieb M, Wiesweg M, et al
    (68)Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.
    J Nucl Med. 2023 Jul 20:jnumed.123.265664. doi: 10.2967/jnumed.123.265664.
    PubMed     Abstract available


  215. GONDRY O, Xavier C, Raes L, Heemskerk J, et al
    Phase I Study of [(68)Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I).
    J Nucl Med. 2023 Jul 20:jnumed.122.264853. doi: 10.2967/jnumed.122.264853.
    PubMed     Abstract available


  216. REZAZADEH F, Ramos N, Saliganan AD, Al-Hallak N, et al
    Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease.
    J Nucl Med. 2023 Jul 20:jnumed.123.265649. doi: 10.2967/jnumed.123.265649.
    PubMed     Abstract available


  217. KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al
    Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
    J Nucl Med. 2023 Jul 20:jnumed.123.265771. doi: 10.2967/jnumed.123.265771.
    PubMed     Abstract available


  218. CHEN M, Fu Y, Peng S, Zang S, et al
    The Association Between [(68)Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy.
    J Nucl Med. 2023 Jul 20:jnumed.122.265368. doi: 10.2967/jnumed.122.265368.
    PubMed     Abstract available


  219. LIN Z, Zhu W, Zhang J, Miao W, et al
    Head-to-Head Comparison of (68)Ga-NODAGA-JR11 and (68)Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study.
    J Nucl Med. 2023 Jul 20:jnumed.122.264890. doi: 10.2967/jnumed.122.264890.
    PubMed     Abstract available


  220. MA J, Yang Q, Huo L, Dai J, et al
    Performance of (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Evaluation of Erdheim-Chester Disease: A Comparison with (18)F-FDG PET/CT.
    J Nucl Med. 2023 Jul 20:jnumed.123.265691. doi: 10.2967/jnumed.123.265691.
    PubMed     Abstract available


  221. AUDITORE L, Pistone D, Italiano A, Amato E, et al
    Monte Carlo Simulations Corroborate PET-Measured Discrepancies in Activity Assessments of Commercial (90)Y Vials.
    J Nucl Med. 2023 Jul 13:jnumed.123.265494. doi: 10.2967/jnumed.123.265494.
    PubMed     Abstract available


  222. ALHUSEINALKHUDHUR A, Lindman H, Liss P, Sundin T, et al
    Human Epidermal Growth Factor Receptor 2-Targeting [(68)Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer.
    J Nucl Med. 2023 Jul 13:jnumed.122.265364. doi: 10.2967/jnumed.122.265364.
    PubMed     Abstract available


  223. JERN P, Chen J, Tuisku J, Saanijoki T, et al
    Endogenous Opioid Release After Orgasm in Man: A Combined PET/Functional MRI Study.
    J Nucl Med. 2023 Jul 13:jnumed.123.265512. doi: 10.2967/jnumed.123.265512.
    PubMed     Abstract available


  224. COOK BE, Nag S, Arakawa R, Lin EY, et al
    Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain.
    J Nucl Med. 2023 Jul 6:jnumed.122.265225. doi: 10.2967/jnumed.122.265225.
    PubMed     Abstract available


  225. PIJL JP, Glaudemans AWJM, Gheysens O, Slart RHJA, et al
    Importance of Blood Glucose Management Before (18)F-FDG PET/CT in 322 Patients with Bacteremia of Unknown Origin.
    J Nucl Med. 2023 Jul 6:jnumed.122.264839. doi: 10.2967/jnumed.122.264839.
    PubMed     Abstract available


  226. STRAUB M, Kupferschlager J, Serna Higuita LM, Weissinger M, et al
    Dual-Time-Point Posttherapy (177)Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome.
    J Nucl Med. 2023 Jul 6:jnumed.122.264770. doi: 10.2967/jnumed.122.264770.
    PubMed     Abstract available


  227. DUIN JJ, de Barros HA, Donswijk ML, Schaake EE, et al
    The Diagnostic Value of the Sentinel Node Procedure to Detect Occult Lymph Node Metastases in PSMA PET/CT Node-Negative Prostate Cancer Patients.
    J Nucl Med. 2023 Jul 6:jnumed.123.265556. doi: 10.2967/jnumed.123.265556.
    PubMed     Abstract available


  228. METSER U, Kulanthaivelu R, Salawu A, Razak A, et al
    [(18)F]FDG PET/CT in the Initial Staging and Restaging of Soft-Tissue or Bone Sarcoma in Patients with Negative or Equivocal Findings for Metastases or Limited Recurrence on Conventional Work-up: Results of a Prospective Multicenter Registry.
    J Nucl Med. 2023 Jul 6:jnumed.122.265278. doi: 10.2967/jnumed.122.265278.
    PubMed     Abstract available


  229. BUCK AK, Serfling SE, Kraus S, Samnick S, et al
    Theranostics in Hematooncology.
    J Nucl Med. 2023;64:1009-1016.
    PubMed     Abstract available


  230. WATANABE M, Grafe H, Theysohn J, Schaarschmidt B, et al
    Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with (90)Y Glass Microspheres.
    J Nucl Med. 2023;64:1102-1108.
    PubMed     Abstract available


  231. ORA M, Soni N, Nazar AH, Dixit M, et al
    Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions.
    J Nucl Med. 2023;64:1001-1008.
    PubMed     Abstract available


  232. BROSCH-LENZ J, Ke S, Wang H, Frey E, et al
    An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 2: Overall Variabilities in Absorbed Dose.
    J Nucl Med. 2023;64:1109-1116.
    PubMed     Abstract available


    June 2023
  233. BROWN EL, Shmuel S, Mandleywala K, Panikar SS, et al
    Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.
    J Nucl Med. 2023 Jun 29:jnumed.122.265172. doi: 10.2967/jnumed.122.265172.
    PubMed     Abstract available


  234. CHEN X, Wang S, Lai Y, Wang G, et al
    Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of (68)Ga-FAPI PET/CT and (18)F-FDG PET/CT.
    J Nucl Med. 2023 Jun 29:jnumed.123.265530. doi: 10.2967/jnumed.123.265530.
    PubMed     Abstract available


  235. BAILEY DL
    Radiopharmaceutical Extravasations Can Have Consequences.
    J Nucl Med. 2023 Jun 29:jnumed.123.265717. doi: 10.2967/jnumed.123.265717.
    PubMed    


  236. HAGENS MJ, Luining WI, Jager A, Donswijk ML, et al
    The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer.
    J Nucl Med. 2023 Jun 29:jnumed.122.265205. doi: 10.2967/jnumed.122.265205.
    PubMed     Abstract available


  237. PARIHAR AS, Raymond-Schmidt L, Crandall JP, Dehdashti F, et al
    Reply: Radiopharmaceutical Extravasations Can Have Consequences.
    J Nucl Med. 2023 Jun 29:jnumed.123.265920. doi: 10.2967/jnumed.123.265920.
    PubMed    


  238. MILOSEVIC A, Styczen H, Grueneisen J, Li Y, et al
    Evaluation of [(68)Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space.
    J Nucl Med. 2023 Jun 29:jnumed.123.265424. doi: 10.2967/jnumed.123.265424.
    PubMed     Abstract available


  239. RASINSKI P, Af Buren S, Holstensson M, Nilsson T, et al
    Tumor Characterization by [(68)Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial.
    J Nucl Med. 2023 Jun 22:jnumed.123.265481. doi: 10.2967/jnumed.123.265481.
    PubMed     Abstract available


  240. ZAUN G, Weber M, Metzenmacher M, Wiesweg M, et al
    SUV(max) Above 20 in (18)F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary.
    J Nucl Med. 2023 Jun 15:jnumed.122.265161. doi: 10.2967/jnumed.122.265161.
    PubMed     Abstract available


  241. UNTERRAINER LM, Sisk AE Jr, Czernin J, Shuch BM, et al
    [(68)Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis.
    J Nucl Med. 2023 Jun 15:jnumed.123.265640. doi: 10.2967/jnumed.123.265640.
    PubMed    


  242. HARADA R, Lerdsirisuk P, Shimizu Y, Yokoyama Y, et al
    Preclinical Characterization of the Tau PET Tracer [(18)F]SNFT-1: Comparison of Tau PET Tracers.
    J Nucl Med. 2023 Jun 15:jnumed.123.265593. doi: 10.2967/jnumed.123.265593.
    PubMed     Abstract available


  243. MACEDO AC, Tissot C, Therriault J, Servaes S, et al
    The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework.
    J Nucl Med. 2023 Jun 15:jnumed.122.265200. doi: 10.2967/jnumed.122.265200.
    PubMed     Abstract available


  244. WASS G, Clifford K, Subramaniam RM
    Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis.
    J Nucl Med. 2023 Jun 8:jnumed.123.265471. doi: 10.2967/jnumed.123.265471.
    PubMed     Abstract available


  245. KARIMZADEH A, Heck M, Tauber R, Solaris E, et al
    The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
    J Nucl Med. 2023 Jun 8:jnumed.122.265346. doi: 10.2967/jnumed.122.265346.
    PubMed     Abstract available


  246. SUNDAR LKS, Lassen ML, Gutschmayer S, Ferrara D, et al
    Fully Automated, Fast Motion Correction of Dynamic Whole-Body and Total-Body PET/CT Imaging Studies.
    J Nucl Med. 2023 Jun 8:jnumed.122.265362. doi: 10.2967/jnumed.122.265362.
    PubMed     Abstract available


  247. WATABE T, Naka S, Tatsumi M, Kamiya T, et al
    Initial Evaluation of [(18)F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions.
    J Nucl Med. 2023 Jun 2:jnumed.123.265486. doi: 10.2967/jnumed.123.265486.
    PubMed     Abstract available


  248. SELFRIDGE AR, Spencer BA, Abdelhafez YG, Nakagawa K, et al
    Facial Anonymization and Privacy Concerns in Total-Body PET/CT.
    J Nucl Med. 2023 Jun 2:jnumed.122.265280. doi: 10.2967/jnumed.122.265280.
    PubMed     Abstract available


  249. MIKALSEN LTG, Kvassheim M, Stokke C
    Optimized SPECT Imaging of (224)Ra alpha-Particle Therapy by (212)Pb Photon Emissions.
    J Nucl Med. 2023 Jun 2:jnumed.122.264455. doi: 10.2967/jnumed.122.264455.
    PubMed     Abstract available


  250. CARTER LM, Ocampo Ramos JC, Olguin EA, Brown JL, et al
    MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals.
    J Nucl Med. 2023 Jun 2:jnumed.122.264230. doi: 10.2967/jnumed.122.264230.
    PubMed     Abstract available


  251. GHESANI M
    Transforming the Science and Practice of Nuclear Medicine.
    J Nucl Med. 2023;64:829-830.
    PubMed    


  252. GOCOCO-BENORE DA, Kuhlman J, Parent EE, Sharma A, et al
    Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden.
    J Nucl Med. 2023;64:880-884.
    PubMed     Abstract available


  253. PANDIT-TASKAR N, Grkovski M, Zanzonico PB, Pentlow KS, et al
    Radioimmunoscintigraphy and Pretreatment Dosimetry of (131)I-Omburtamab for Planning Treatment of Leptomeningeal Disease.
    J Nucl Med. 2023;64:946-950.
    PubMed     Abstract available


  254. MARIC I, Weber M, Prochnow A, Schmitz J, et al
    Efficacy and Safety of (124)I-MIBG Dosimetry-Guided High-Activity (131)I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma.
    J Nucl Med. 2023;64:885-891.
    PubMed     Abstract available


  255. MALIHA PG, Jafarvard M, Czernin J, Calais J, et al
    Incidental Focal (68)Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion.
    J Nucl Med. 2023;64:992.
    PubMed    


    May 2023
  256. SUNDERLAND JJ, Graves SA, York DM, Mundt CA, et al
    Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose.
    J Nucl Med. 2023 May 25:265891. doi: 10.2967/jnumed.123.265891.
    PubMed     Abstract available


  257. KUO PH, Yoo DC, Avery R, Seltzer M, et al
    A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy.
    J Nucl Med. 2023 May 25:265077. doi: 10.2967/jnumed.122.265077.
    PubMed     Abstract available


  258. MALIHA PG, Mendelsohn AH, Czernin J, Howard T, et al
    Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [(68)Ga]Ga-FAPI-46 PET-Positive and [(18)F]FDG PET-Negative.
    J Nucl Med. 2023 May 25:265498. doi: 10.2967/jnumed.123.265498.
    PubMed    


  259. BERLINER C, Steinhelfer L, Chantadisai M, Kroenke M, et al
    Delayed Imaging Improves Lesion Detectability in [(99m)Tc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer.
    J Nucl Med. 2023 May 25:265252. doi: 10.2967/jnumed.122.265252.
    PubMed     Abstract available


  260. MEI R, Kessler L, Pabst KM, Weber M, et al
    (68)Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study.
    J Nucl Med. 2023 May 25:265245. doi: 10.2967/jnumed.122.265245.
    PubMed     Abstract available


  261. SEBAN RD, Champion L, Bellesoeur A, Vincent-Salomon A, et al
    Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients.
    J Nucl Med. 2023 May 25:265434. doi: 10.2967/jnumed.123.265434.
    PubMed    


  262. GALLDIKS N, Langen KJ
    Hybrid (18)F-FET PET and Perfusion MRI to Differentiate Disease Progression from Treatment-Related Changes in Malignant Brain Tumors.
    J Nucl Med. 2023 May 18:265647. doi: 10.2967/jnumed.123.265647.
    PubMed    


  263. OH C, Bishop MW, Cho SY, Im HJ, et al
    (18)F-FDG PET/CT in the Management of Osteosarcoma.
    J Nucl Med. 2023 May 18:265592. doi: 10.2967/jnumed.123.265592.
    PubMed     Abstract available


  264. BOBBA KN, Bidkar AP, Meher N, Fong C, et al
    Evaluation of (134)Ce/(134)La as a PET Imaging Theranostic Pair for (225)Ac alpha-Radiotherapeutics.
    J Nucl Med. 2023 May 18:265355. doi: 10.2967/jnumed.122.265355.
    PubMed     Abstract available


  265. LEUPE H, Ahenkorah S, Dekervel J, Unterrainer M, et al
    (18)F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use.
    J Nucl Med. 2023 May 11:265622. doi: 10.2967/jnumed.123.265622.
    PubMed     Abstract available


  266. LOFT M, Ladefoged CN, Johnbeck CB, Carlsen EA, et al
    An Investigation of Lesion Detection Accuracy for Artificial Intelligence-Based Denoising of Low-Dose (64)Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms.
    J Nucl Med. 2023 May 11:264826. doi: 10.2967/jnumed.122.264826.
    PubMed     Abstract available


  267. EVANGELISTA L
    PSMA PET/CT and Therapy Response Evaluation in Metastatic Prostate Cancer: Is It Time to Surpass the Old Way?
    J Nucl Med. 2023 May 11:265308. doi: 10.2967/jnumed.122.265308.
    PubMed    


  268. URBAIN JL, Scott AM, Lee ST, Buscombe J, et al
    Theranostic Radiopharmaceuticals: A Universal Challenging Educational Paradigm in Nuclear Medicine.
    J Nucl Med. 2023 May 4:jnumed.123.265603. doi: 10.2967/jnumed.123.265603.
    PubMed    


  269. SOLEIMANI-MEIGOONI DN, Rabinovici GD
    Tau PET Visual Reads: Research and Clinical Applications and Future Directions.
    J Nucl Med. 2023;64:822-824.
    PubMed    


  270. IZQUIERDO-GARCIA D, Desogere P, Fur ML, Shuvaev S, et al
    Biodistribution, Dosimetry, and Pharmacokinetics of (68)Ga-CBP8: A Type I Collagen-Targeted PET Probe.
    J Nucl Med. 2023;64:775-781.
    PubMed     Abstract available


    April 2023
  271. COLOVIC M, Yang H, Southcott L, Merkens H, et al
    Comparative Evaluation of [(18)F]5-Fluoroaminosuberic Acid and (4S)-4-3-[(18)F]fluoropropyl)-l-Glutamate as System xC--Targeting Radiopharmaceuticals.
    J Nucl Med. 2023 Apr 28:jnumed.122.265254. doi: 10.2967/jnumed.122.265254.
    PubMed     Abstract available


  272. WANG Y, Spencer BA, Schmall J, Li E, et al
    High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections.
    J Nucl Med. 2023 Apr 28:jnumed.122.264810. doi: 10.2967/jnumed.122.264810.
    PubMed     Abstract available


  273. SMITH NJ, Deaton TK, Territo W, Graner B, et al
    Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases.
    J Nucl Med. 2023 Apr 28:jnumed.122.265149. doi: 10.2967/jnumed.122.265149.
    PubMed     Abstract available


  274. KESLER M, Cohen D, Levine C, Sarid D, et al
    Staging Prostate Cancer with (68)Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?
    J Nucl Med. 2023 Apr 28:jnumed.122.265371. doi: 10.2967/jnumed.122.265371.
    PubMed     Abstract available


  275. GALLDIKS N, Lohmann P, Fink GR, Langen KJ, et al
    Amino Acid PET in Neurooncology.
    J Nucl Med. 2023 Apr 13:264859. doi: 10.2967/jnumed.122.264859.
    PubMed     Abstract available


  276. IAGARU A
    2022 SNMMI Highlights Lecture: General Nuclear Medicine.
    J Nucl Med. 2023 Apr 13:265758. doi: 10.2967/jnumed.123.265758.
    PubMed     Abstract available


  277. MORRIS MJ, Calais J, Czernin J
    Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin.
    J Nucl Med. 2023 Apr 13:265684. doi: 10.2967/jnumed.123.265684.
    PubMed    


  278. PABST KM, Trajkovic-Arsic M, Cheung PFY, Ballke S, et al
    Superior Tumor Detection for (68)Ga-FAPI-46 Versus (18)F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma.
    J Nucl Med. 2023 Apr 6:jnumed.122.265215. doi: 10.2967/jnumed.122.265215.
    PubMed     Abstract available


  279. SLART RHJA, Nienhuis PH, Glaudemans AWJM, Brouwer E, et al
    Role of (18)F-FDG PET/CT in Large Vessel Vasculitis and Polymyalgia Rheumatica.
    J Nucl Med. 2023;64:515-521.
    PubMed     Abstract available


  280. DONOHOE KJ, Carroll BJ, Chung DKV, Dibble EH, et al
    Summary: Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema.
    J Nucl Med. 2023;64:525-528.
    PubMed     Abstract available


  281. MOISIO O, Virta J, Yatkin E, Liljenback H, et al
    Preclinical Evaluation of (89)Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis.
    J Nucl Med. 2023;64:555-560.
    PubMed     Abstract available


  282. GANGULY T, Bauer N, Davis RA, Foster CC, et al
    Preclinical Evaluation of (68)Ga- and (177)Lu-Labeled Integrin alpha(v)beta(6)-Targeting Radiotheranostic Peptides.
    J Nucl Med. 2023;64:639-644.
    PubMed     Abstract available


    March 2023
  283. FAYN S, King AP, Gutsche NT, Duan Z, et al
    Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET.
    J Nucl Med. 2023 Mar 30:jnumed.122.265171. doi: 10.2967/jnumed.122.265171.
    PubMed     Abstract available


  284. GUEHL NJ, Dhaynaut M, Hanseeuw BJ, Moon SH, et al
    Measurement of Cerebral Perfusion Indices from the Early Phase of [(18)F]MK6240 Dynamic Tau PET Imaging.
    J Nucl Med. 2023 Mar 30:jnumed.122.265072. doi: 10.2967/jnumed.122.265072.
    PubMed     Abstract available


  285. HOTTA M, Gafita A, Murthy V, Benz MR, et al
    PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [(177)Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study.
    J Nucl Med. 2023 Mar 30:jnumed.122.265242. doi: 10.2967/jnumed.122.265242.
    PubMed     Abstract available


  286. BUVAT I, Weber W
    Nuclear Medicine from a Novel Perspective: Buvat and Weber Talk with OpenAI's ChatGPT.
    J Nucl Med. 2023 Mar 23:jnumed.123.265636. doi: 10.2967/jnumed.123.265636.
    PubMed    


  287. ULANER GA, Mankoff DA, Clark AS, Fowler AM, et al
    Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16alpha-(18)F-Fluoro-17beta-Fluoroestradiol.
    J Nucl Med. 2023;64:351-354.
    PubMed     Abstract available


  288. PARIHAR AS, Haq A, Wahl RL, Jahromi AH, et al
    Progression or Response: New Liver Lesions in a Patient with Responding Hodgkin Lymphoma.
    J Nucl Med. 2023;64:500.
    PubMed    


  289. IONESCU TM, Amend M, Watabe T, Hatazawa J, et al
    Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of 3,4-Methylenedioxymethamphetamine.
    J Nucl Med. 2023;64:466-471.
    PubMed     Abstract available


  290. CIVAN C, Kasper S, Berliner C, Fragoso-Costa P, et al
    PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study.
    J Nucl Med. 2023;64:372-378.
    PubMed     Abstract available


  291. KLEIN JS, Kim TJ, Pratx G
    Development of a Lensless Radiomicroscope for Cellular-Resolution Radionuclide Imaging.
    J Nucl Med. 2023;64:479-484.
    PubMed     Abstract available


    February 2023
  292. AL-IBRAHEEM A, Doudeen RM, Juaidi D, Abufara A, et al
    (161)Tb-PSMA Radioligand Therapy: First-in-human SPECT/CT Imaging.
    J Nucl Med. 2023 Feb 9:jnumed.122.265291. doi: 10.2967/jnumed.122.265291.
    PubMed    


  293. SONNI I, Dal Pra A, O'Connell DP, Ells Z, et al
    PSMA PET/CT-based Atlas for Prostatic Bed Recurrence after Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines.
    J Nucl Med. 2023 Feb 9:jnumed.122.265025. doi: 10.2967/jnumed.122.265025.
    PubMed     Abstract available


  294. KASHYAP R, Ravi Kumar AS
    Could FAP-targeted molecular imaging replace FDG for standard-of-care oncologic PET?
    J Nucl Med. 2023 Feb 2:jnumed.122.265003. doi: 10.2967/jnumed.122.265003.
    PubMed    


  295. CHIARAVALLOTI A, Filippi L, Pagani M, Schillaci O, et al
    Functional imaging of chemo-brain: usefulness of Nuclear Medicine in the fog coming after cancer.
    J Nucl Med. 2023 Feb 2:jnumed.121.263294. doi: 10.2967/jnumed.121.263294.
    PubMed     Abstract available


  296. TRAPP C, Oliinyk D, Rogowski P, Von Bestenbostel R, et al
    An analysis of PSMA-PET/CT-positive lymph node distribution and their coverage by different elective nodal radiation volumes in postoperative prostate cancer patients.
    J Nucl Med. 2023 Feb 2:jnumed.122.265159. doi: 10.2967/jnumed.122.265159.
    PubMed     Abstract available


  297. HOPE TA, Allen-Auerbach M, Bodei L, Calais J, et al
    SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors.
    J Nucl Med. 2023;64:204-210.
    PubMed    


  298. O'DONOGHUE J, Zanzonico P, Humm J, Kesner A, et al
    Reply: Dosimetry in Radiopharmaceutical Therapy.
    J Nucl Med. 2023;64:339-340.
    PubMed    


  299. STABIN M
    Dosimetry in Radiopharmaceutical Therapy.
    J Nucl Med. 2023;64:339.
    PubMed    


  300. FLORES S, Chen CD, Su Y, Dincer A, et al
    Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease.
    J Nucl Med. 2023;64:287-293.
    PubMed     Abstract available


  301. TREMBLAY S, Beaudoin JF, Belissant Benesty O, Ait-Mohand S, et al
    (68)Ga-DOTATATE Prepared from Cyclotron-Produced (68)Ga: An Integrated Solution from Cyclotron Vault to Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients.
    J Nucl Med. 2023;64:232-238.
    PubMed     Abstract available


  302. RICARD F, Barrington S, Korn R, Brueggenwerth G, et al
    Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical).
    J Nucl Med. 2023;64:239-243.
    PubMed     Abstract available


    January 2023
  303. ISSER S, Maurer A, Reischl G, Schaller M, et al
    Radiolabeled GPVI-Fc for PET imaging of multiple extracellular matrix fibers: A new look into pulmonary fibrosis progression.
    J Nucl Med. 2023 Jan 26:jnumed.122.264552. doi: 10.2967/jnumed.122.264552.
    PubMed     Abstract available


  304. SELLMANN T, Staak F, Maurer C, Rott G, et al
    Incidental detection of a tenosynovial giant cell tumour of the thigh on [(68)Ga]Ga-FAPI PET/CT: presentation of an unusual case.
    J Nucl Med. 2023 Jan 26:jnumed.118.207761. doi: 10.2967/jnumed.118.207761.
    PubMed    


  305. AL JALALI V, Wasinger G, Rasul S, Grubmueller B, et al
    Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naive prostate cancer.
    J Nucl Med. 2023 Jan 19:jnumed.122.264981. doi: 10.2967/jnumed.122.264981.
    PubMed     Abstract available


  306. VON GUGGENBERG E, Uprimny C, Klingler M, Warwitz B, et al
    Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the (68)Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer.
    J Nucl Med. 2023 Jan 19:jnumed.122.264977. doi: 10.2967/jnumed.122.264977.
    PubMed     Abstract available


  307. CALDERONI L, Maietti E, Farolfi A, Mei R, et al
    Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
    J Nucl Med. 2023 Jan 12:jnumed.122.264964. doi: 10.2967/jnumed.122.264964.
    PubMed     Abstract available


  308. SORENSEN J, Bergsten J, Baron T, Orndahl LH, et al
    Myocardial external efficiency in asymptomatic severe primary mitral regurgitation using (11)C-acetate positron emission tomography.
    J Nucl Med. 2023 Jan 5:jnumed.122.264945. doi: 10.2967/jnumed.122.264945.
    PubMed     Abstract available


  309. ORCIUOLO J, Sharma A, Parent EE, Accurso JM, et al
    Incidental Airway Findings on PET/CT with F-18 PSMA.
    J Nucl Med. 2023 Jan 5:jnumed.122.265270. doi: 10.2967/jnumed.122.265270.
    PubMed    


  310. FOX JJ, Mauguen A, Ito K, Gupta D, et al
    Long-term prognostic value of 82Rubidium PET/CT-determined myocardial perfusion and flow reserve in cancer patients.
    J Nucl Med. 2023 Jan 5:jnumed.122.264795. doi: 10.2967/jnumed.122.264795.
    PubMed     Abstract available


  311. CHEN R, Yang X, Ng YL, Yu X, et al
    First total-body kinetic modeling and parametric imaging of dynamic (68)Ga-FAPI-04 PET in pancreatic and gastric cancer.
    J Nucl Med. 2023 Jan 5:jnumed.122.264988. doi: 10.2967/jnumed.122.264988.
    PubMed     Abstract available


  312. SONG K, Bodei L, Czernin J
    From Physician to Leader in Global Research and Development: A Conversation Between Ken Song, Lisa Bodei, and Johannes Czernin.
    J Nucl Med. 2023;64:8-11.
    PubMed    


  313. SCHODER H
    2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2.
    J Nucl Med. 2023;64:2-7.
    PubMed     Abstract available


  314. RUDDY TD, Al-Mallah M, Arrighi JA, Bois JP, et al
    SNMMI/ACR/ASNC/SCMR Joint Credentialing Statement for Cardiac PET/MRI: Endorsed by the American Heart Association.
    J Nucl Med. 2023;64:149-152.
    PubMed    


  315. RICARD F, Cheson B, Barrington S, Trotman J, et al
    Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).
    J Nucl Med. 2023;64:102-108.
    PubMed     Abstract available


  316. MC LARNEY BE, Zhang Q, Pratt EC, Skubal M, et al
    Detection of Shortwave-Infrared Cerenkov Luminescence from Medical Isotopes.
    J Nucl Med. 2023;64:177-182.
    PubMed     Abstract available


    December 2022
  317. KANG HG, Tashima H, Wakizaka H, Nishikido F, et al
    Submillimeter resolution positron emission tomography for high-sensitivity mouse brain imaging.
    J Nucl Med. 2022 Dec 29:jnumed.122.264433. doi: 10.2967/jnumed.122.264433.
    PubMed     Abstract available


  318. HIRMAS N, Hamacher R, Sraieb M, Ingenwerth M, et al
    Fibroblast activation protein positron emission tomography and histopathology in a single-center database of 324 patients and 21 tumor entities.
    J Nucl Med. 2022 Dec 29:jnumed.122.264689. doi: 10.2967/jnumed.122.264689.
    PubMed     Abstract available


  319. LUNGER L, Chantadisai M, Karimzadeh A, Rauscher I, et al
    The prognostic role of (68)Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy.
    J Nucl Med. 2022 Dec 29:jnumed.122.264962. doi: 10.2967/jnumed.122.264962.
    PubMed     Abstract available


  320. NABAVIZADEH A, Bagley SJ, Doot RK, Ware JB, et al
    Distinguishing Progression from Pseudoprogression in Glioblastoma Using (18)F-Fluciclovine PET.
    J Nucl Med. 2022 Dec 22:jnumed.122.264812. doi: 10.2967/jnumed.122.264812.
    PubMed     Abstract available


  321. MICHAUD L, Bantilan K, Mauguen A, Moskowitz CH, et al
    Prognostic value of (18)F-FDG PET/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen.
    J Nucl Med. 2022 Dec 22:jnumed.122.264740. doi: 10.2967/jnumed.122.264740.
    PubMed     Abstract available


  322. SIMPSON SR, Kesterson AE, Wilde JH, Qureshi Z, et al
    Imaging Diverse Pathogenic Bacteria in vivo with [(18)F]fluoromannitol Positron Emission Tomography.
    J Nucl Med. 2022 Dec 15:jnumed.122.264854. doi: 10.2967/jnumed.122.264854.
    PubMed     Abstract available


  323. VAN DER POL JAJ, Mottaghy FM
    Extravasation of diagnostic radiopharmaceuticals, a wolf in sheep's clothing?
    J Nucl Med. 2022 Dec 15:jnumed.122.265038. doi: 10.2967/jnumed.122.265038.
    PubMed    


  324. SEIFERT R, Telli T, Hadaschik B, Fendler WP, et al
    Is (18)F-FDG PET needed to assess (177)Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis.
    J Nucl Med. 2022 Dec 15:jnumed.122.264741. doi: 10.2967/jnumed.122.264741.
    PubMed     Abstract available


  325. HUANG J, Mitchell AJ, Garcia EV, Cooke CD, et al
    Left Ventricular Strain from Myocardial Perfusion Positron Emission Tomography imaging: Method Development and Comparison to 2-Dimensional Echocardiography.
    J Nucl Med. 2022 Dec 15:jnumed.122.264516. doi: 10.2967/jnumed.122.264516.
    PubMed     Abstract available


  326. SABOURY B, Bradshaw T, Boellaard R, Buvat I, et al
    Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem.
    J Nucl Med. 2022 Dec 15:jnumed.121.263703. doi: 10.2967/jnumed.121.263703.
    PubMed     Abstract available


  327. SCHLURMANN T, Waschulzik B, Combs S, Gempt J, et al
    Diagnostic utility of amino acid PET in the differential diagnosis of recurrent brain metastases and treatment-related changes: a meta-analysis.
    J Nucl Med. 2022 Dec 2:jnumed.122.264803. doi: 10.2967/jnumed.122.264803.
    PubMed     Abstract available


  328. SHIYAM SUNDAR LK, Hacker M, Beyer T
    Whole-body PET imaging: A catalyst for whole-person research?
    J Nucl Med. 2022 Dec 2:jnumed.122.264555. doi: 10.2967/jnumed.122.264555.
    PubMed     Abstract available


  329. SEIFERT R, Telli T, Opitz M, Barbato F, et al
    Non-specific PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scan and MRI triple validation in patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2022 Dec 2:jnumed.118.215434. doi: 10.2967/jnumed.118.215434.
    PubMed     Abstract available


  330. BAILEY DL, Willowson KP, Harris M, Biggin C, et al
    (64)Cu Treatment Planning and (67)Cu Therapy with Radiolabelled SARTATE ([(64)Cu/(67)Cu]MeCOSAR-Octreotate) in Subjects with Unresectable Multifocal Meningioma - Initial Results for Human Imaging, Safety, Biodistribution and Radiation Dosimetry.
    J Nucl Med. 2022 Dec 2:jnumed.122.264586. doi: 10.2967/jnumed.122.264586.
    PubMed     Abstract available


  331. SCHODER H
    2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 1.
    J Nucl Med. 2022;63:13N-18N.
    PubMed     Abstract available


  332. SCHMIDKONZ C, Kuwert T, Atzinger A, Cordes M, et al
    Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging.
    J Nucl Med. 2022;63:1786-1792.
    PubMed     Abstract available


  333. AHMED H, Zheng MQ, Smart K, Fang H, et al
    Evaluation of (rac)-, (R)-, and (S)-(18)F-OF-NB1 for Imaging GluN2B Subunit-Containing N-Methyl-d-Aspartate Receptors in Nonhuman Primates.
    J Nucl Med. 2022;63:1912-1918.
    PubMed     Abstract available


  334. HERRMANN K, Giovanella L, Santos A, Gear J, et al
    Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
    J Nucl Med. 2022;63:1836-1843.
    PubMed     Abstract available


    November 2022
  335. OLIVIER P, Giraudet AL, Skanjeti A, Merlin C, et al
    Phase III study of (18)F-PSMA-1007 versus (18)F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, cross-over, multicenter study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264743. doi: 10.2967/jnumed.122.264743.
    PubMed     Abstract available


  336. GNESIN S, Mikell JK, Conti M, Prior JO, et al
    A multicenter study on observed discrepancies between vendor-stated and PET measured (90)Y activities for both glass and resin microsphere devices.
    J Nucl Med. 2022 Nov 23:jnumed.122.264458. doi: 10.2967/jnumed.122.264458.
    PubMed     Abstract available


  337. LUMISH MA, Maron SB, Paroder V, Chou JF, et al
    Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: a pilot study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264470. doi: 10.2967/jnumed.122.264470.
    PubMed     Abstract available


  338. BACKHAUS P, Burg MC, Asmus I, Pixberg M, et al
    Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264871. doi: 10.2967/jnumed.122.264871.
    PubMed     Abstract available


  339. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
    A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264448. doi: 10.2967/jnumed.122.264448.
    PubMed     Abstract available


  340. TISSOT C, Servaes S, Lussier FZ, Ferrari-Souza JP, et al
    The association of age-related and off-target retention with longitudinal quantification of [(18)F]MK6240 tau-PET in target regions.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264434. doi: 10.2967/jnumed.122.264434.
    PubMed     Abstract available


  341. DEMMERT TT, Maric I, Pomykala KL, Lueckerath K, et al
    Novel (68)Ga-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264872. doi: 10.2967/jnumed.122.264872.
    PubMed     Abstract available


  342. NAEIMI M, Choyke PL, Dendl K, Mori Y, et al
    3-time-point PET-analysis of FAPI-46 in a variety of cancers.
    J Nucl Med. 2022 Nov 10. pii: jnumed.122.264941. doi: 10.2967/jnumed.122.264941.
    PubMed     Abstract available


  343. KREBS S, Schwartz J, Grommes C, Young RJ, et al
    Detecting CXCR4 expression in meningioma on (68)Ga-Pentixafor PET.
    J Nucl Med. 2022 Nov 10. pii: jnumed.122.265127. doi: 10.2967/jnumed.122.265127.
    PubMed    


  344. FRAGOSO COSTA P, Pullen L, Kesch C, Krafft U, et al
    F18-PSMA Cerenkov luminescence and flexible autoradiography Imaging in a prostate cancer mouse model and first results of a radical prostatectomy feasibility study in men.
    J Nucl Med. 2022 Nov 10. pii: jnumed.122.264670. doi: 10.2967/jnumed.122.264670.
    PubMed     Abstract available


  345. KANG SK, Kim D, Shin SA, Kim YK, et al
    Fast and accurate amyloid brain PET quantification without MRI using deep neural networks.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264414. doi: 10.2967/jnumed.122.264414.
    PubMed     Abstract available


  346. LAWAL IO, Adediran OA, Jani AB, Goyal S, et al
    Differences in Failure-free Survival Post Salvage Radiotherapy Guided by Conventional Imaging Versus (18)F-fluciclovine PET/CT in Post-prostatectomy Patients: a Post-hoc Sub-stratification Analysis of the EMPIRE-1 Trial.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264832. doi: 10.2967/jnumed.122.264832.
    PubMed     Abstract available


  347. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
    A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264783. doi: 10.2967/jnumed.122.264783.
    PubMed     Abstract available



  348. SNMMI Newsline.
    J Nucl Med. 2022;63:15N-26N.
    PubMed    


  349. PRICE J
    2022 SNMMI Highlights Lecture: Neuroscience.
    J Nucl Med. 2022;63:15N-22N.
    PubMed     Abstract available


  350. MILLER RJH, Kuronuma K, Singh A, Otaki Y, et al
    Explainable Deep Learning Improves Physician Interpretation of Myocardial Perfusion Imaging.
    J Nucl Med. 2022;63:1768-1774.
    PubMed     Abstract available


  351. SHUKURI M, Mawatari A, Takatani S, Tahara T, et al
    Synthesis and Preclinical Evaluation of (18)F-Labeled Ketoprofen Methyl Esters for Cyclooxygenase-1 Imaging in Neuroinflammation.
    J Nucl Med. 2022;63:1761-1767.
    PubMed     Abstract available


  352. BRIER MR, Hamdi M, Rajamanikam J, Zhao H, et al
    Phase 1 Evaluation of (11)C-CS1P1 to Assess Safety and Dosimetry in Human Participants.
    J Nucl Med. 2022;63:1775-1782.
    PubMed     Abstract available


    October 2022
  353. KIND F, Eder AC, Jilg CA, Hartrampf P, et al
    Prognostic value of tumor volume assessment on PSMA PET after (177)Lu-PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0.
    J Nucl Med. 2022 Oct 27. pii: jnumed.122.264489. doi: 10.2967/jnumed.122.264489.
    PubMed     Abstract available


  354. COOK GJR, Wong WL, Sanghera B, Mangar S, et al
    Eligibility for (177)Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of (68)Ga-PSMA-11 and (99m)Tc-MIP-1404 in metastatic castrate resistant prostate cancer.
    J Nucl Med. 2022 Oct 27. pii: jnumed.122.264296. doi: 10.2967/jnumed.122.264296.
    PubMed     Abstract available


  355. PAUWELS E, Cleeren F, Tshibangu T, Koole M, et al
    (18)F-AlF-NOTA-octreotide outperforms (68)Ga-DOTA-TATE/-NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study.
    J Nucl Med. 2022 Oct 20. pii: jnumed.122.264563. doi: 10.2967/jnumed.122.264563.
    PubMed     Abstract available


  356. VISSER D, Tuncel H, Ossenkoppele R, Yaqub MM, et al
    Longitudinal tau PET using (18)F-flortaucipir: the Effect of relative Cerebral Blood Flow on (semi)quantitative parameters.
    J Nucl Med. 2022 Oct 20. pii: jnumed.122.263926. doi: 10.2967/jnumed.122.263926.
    PubMed     Abstract available


  357. PHELPS TE, Harmon SA, Mena E, Lindenberg L, et al
    Predicting Outcomes of Indeterminate Bone Lesions on (18)F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer.
    J Nucl Med. 2022 Oct 20. pii: jnumed.122.264334. doi: 10.2967/jnumed.122.264334.
    PubMed     Abstract available


  358. PARIHAR AS, Schmidt LR, Crandall J, Dehdashti F, et al
    Adverse clinical events at the injection site are exceedingly rare following reported radiopharmaceutical extravasation in patients undergoing (99m)Tc-MDP whole body bone scintigraphy: A 12-year experience.
    J Nucl Med. 2022 Oct 20. pii: jnumed.122.264994. doi: 10.2967/jnumed.122.264994.
    PubMed     Abstract available


  359. COOMANS EM, Verberk IMW, Ossenkoppele R, Verfaillie SCJ, et al
    A head-to-head comparison between plasma pTau181 and tau-PET along the Alzheimer's disease continuum.
    J Nucl Med. 2022 Oct 13. pii: jnumed.122.264279. doi: 10.2967/jnumed.122.264279.
    PubMed     Abstract available


  360. SALDARRIAGA VARGAS C, Struelens L, D'Huyvetter M, Caveliers V, et al
    A Realistic Multi-region Mouse Kidney Dosimetry Model to Support the Preclinical Evaluation of Potential Nephrotoxicity of Radiopharmaceutical Therapy.
    J Nucl Med. 2022 Oct 13. pii: jnumed.122.264453. doi: 10.2967/jnumed.122.264453.
    PubMed     Abstract available


  361. HU X, Zhou T, Ren J, Duan J, et al
    Response prediction using (18)F-FAPI-04 PET/CT in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy.
    J Nucl Med. 2022 Oct 13. pii: jnumed.122.264638. doi: 10.2967/jnumed.122.264638.
    PubMed     Abstract available


  362. MILLER RJ, Pieszko K, Shanbhag A, Feher A, et al
    Deep learning coronary artery calcium scores from SPECT/CT attenuation maps improves prediction of major adverse cardiac events.
    J Nucl Med. 2022 Oct 7. pii: jnumed.122.264423. doi: 10.2967/jnumed.122.264423.
    PubMed     Abstract available


  363. VOGSEN M, Harbo F, Jakobsen NM, Nissen HJ, et al
    Response monitoring in metastatic breast cancer - a prospective study comparing (18)F-FDG PET/CT with conventional CT.
    J Nucl Med. 2022 Oct 7. pii: jnumed.121.263358. doi: 10.2967/jnumed.121.263358.
    PubMed     Abstract available


  364. O'DONOGHUE J, Zanzonico P, Humm J, Kesner A, et al
    Dosimetry in Radiopharmaceutical Therapy.
    J Nucl Med. 2022;63:1467-1474.
    PubMed     Abstract available



  365. SNMMI Newsline.
    J Nucl Med. 2022;63:13N-20N.
    PubMed    


  366. FREY KA
    ABNM CertLink: Update and "By the Numbers".
    J Nucl Med. 2022;63:13N.
    PubMed    


  367. GHESANI M
    Making Nuclear Medicine a Household Phrase.
    J Nucl Med. 2022;63:14N.
    PubMed    


  368. BAX JJ, Bengel FM
    Integrating Nuclear Imaging and Cardiology in Clinical Practice: A Conversation Between Jeroen J. Bax and Frank M. Bengel.
    J Nucl Med. 2022;63:1455-1458.
    PubMed    


  369. ALSADIK S, Gnanasegaran G, Chen L, Mandair D, et al
    Safety of Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease.
    J Nucl Med. 2022;63:1503-1508.
    PubMed     Abstract available


  370. SATHEKGE M, Bruchertseifer F, Vorster M, Lawal IO, et al
    mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.
    J Nucl Med. 2022;63:1496-1502.
    PubMed     Abstract available


    September 2022
  371. DERLIN T, Spencer BA, Mamach M, Abdelhafez Y, et al
    Exploring Vessel Wall Biology In Vivo By Ultra-Sensitive Total-Body Positron Emission Tomography.
    J Nucl Med. 2022 Sep 29. pii: jnumed.122.264550. doi: 10.2967/jnumed.122.264550.
    PubMed     Abstract available


  372. SEIBYL JP, DuBois JM, Racine A, Collins J, et al
    A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18-F MK-6240 Positron Emission Tomography.
    J Nucl Med. 2022 Sep 29. pii: jnumed.122.264371. doi: 10.2967/jnumed.122.264371.
    PubMed     Abstract available


  373. SMITH AM, Obuchowski NA, Foster NL, Klein G, et al
    The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264031. doi: 10.2967/jnumed.122.264031.
    PubMed     Abstract available


  374. SHANBHAG AD, Miller RJH, Pieszko K, Lemley M, et al
    Deep Learning-based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264429. doi: 10.2967/jnumed.122.264429.
    PubMed     Abstract available


  375. MORAWITZ J, Sigl B, Rubbert C, Bruckmann NM, et al
    Clinical decision support for axillary lymph node staging in newly diagnosed breast cancer patients based on (18)F-FDG PET/MRI and machine-learning.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264138. doi: 10.2967/jnumed.122.264138.
    PubMed     Abstract available


  376. KARIMZADEH A, Heck M, Tauber R, Knorr K, et al
    (177)Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264402. doi: 10.2967/jnumed.122.264402.
    PubMed     Abstract available


  377. PUUVUORI E, Chiodaroli E, Estrada S, Cheung P, et al
    PET imaging of neutrophil elastase with (11)C-GW457427 in Acute Respiratory Distress Syndrome in pigs.
    J Nucl Med. 2022 Sep 15. pii: jnumed.122.264306. doi: 10.2967/jnumed.122.264306.
    PubMed     Abstract available


  378. TRAUTWEIN NF, Reischl G, Seitz C, Dittmann H, et al
    First in human PET/MRI imaging of in vivo GD2 expression in osteosarcoma.
    J Nucl Med. 2022 Sep 15. pii: jnumed.122.264626. doi: 10.2967/jnumed.122.264626.
    PubMed    


  379. BAILLY M, Thibault F, Metrard G, Courtehoux M, et al
    Precision of Myocardial Blood Flow and Flow Reserve measurement during CZT-SPECT perfusion imaging processing: intra- and inter-observer variability.
    J Nucl Med. 2022 Sep 15. pii: jnumed.122.264454. doi: 10.2967/jnumed.122.264454.
    PubMed     Abstract available


  380. BURTON CS, Frey K, Fahey F, Kaminski MS, et al
    Fetal Dose from Positron Emission Tomography and Computed Tomography in Pregnant Patients.
    J Nucl Med. 2022 Sep 8. pii: jnumed.122.263959. doi: 10.2967/jnumed.122.263959.
    PubMed     Abstract available


  381. JOHN N, Pathmanandavel S, Crumbaker M, Counter W, et al
    (177)Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
    J Nucl Med. 2022 Sep 8. pii: jnumed.122.264677. doi: 10.2967/jnumed.122.264677.
    PubMed     Abstract available


  382. KWEE TC, Almaghrabi M, Kwee RM
    Scientific fraud, publication bias, and honorary authorship in nuclear medicine.
    J Nucl Med. 2022 Sep 8. pii: jnumed.122.264679. doi: 10.2967/jnumed.122.264679.
    PubMed     Abstract available


  383. SUBRAMANIAM RM, DeMora L, Yao M, Yom SS, et al
    (18)F FDG PET/CT Prediction of Treatment Outcomes in HPV-positive, Locally Advanced Oropharyngeal Cancer Receiving De-intensified Therapy: Results from NRG-HN002.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.264424. doi: 10.2967/jnumed.122.264424.
    PubMed     Abstract available


  384. PANG Y, Zhao L, Meng T, Xu W, et al
    PET imaging of fibroblast activation protein in various types of cancers by using (68)Ga-FAP-2286: Comparison with (18)F-FDG and (68)Ga-FAPI-46 in a single-center, prospective study.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.264544. doi: 10.2967/jnumed.122.264544.
    PubMed     Abstract available


  385. BELLAVIA MC, Patel RB, Anderson CJ
    Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.264373. doi: 10.2967/jnumed.122.264373.
    PubMed     Abstract available


  386. SCHOLLHAMMER R, Robert G, Asselineau J, Yacoub M, et al
    Comparison of (68)Ga-PSMA-617 PET/CT and (68)Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.263889. doi: 10.2967/jnumed.122.263889.
    PubMed     Abstract available


  387. ISRAEL O, Czernin J
    A Life in Nuclear Medicine in Israel: A Conversation Between Ora Israel and Johannes Czernin.
    J Nucl Med. 2022;63:1285-1287.
    PubMed    



  388. SNMMI Honors Contributors, Recognizes Scientific Excellence at 2022 Annual Meeting.
    J Nucl Med. 2022;63:11N-13N.
    PubMed    


  389. GHESANI M
    Full Steam Ahead for Nuclear Medicine Therapy.
    J Nucl Med. 2022;63:14N.
    PubMed    



  390. SNMMI Newsline.
    J Nucl Med. 2022;63:11N-22N.
    PubMed    


  391. JHA A, Patel M, Carrasquillo JA, Chen CC, et al
    Choice Is Good at Times: The Emergence of [(64)Cu]Cu-DOTATATE-Based Somatostatin Receptor Imaging in the Era of [(68)Ga]Ga-DOTATATE.
    J Nucl Med. 2022;63:1300-1301.
    PubMed    


  392. CRANDALL JP, Fraum TJ, Wahl RL
    Brown Adipose Tissue: A Protective Mechanism Against "Preprediabetes"?
    J Nucl Med. 2022;63:1433-1440.
    PubMed     Abstract available


  393. DELPASSAND ES, Tworowska I, Esfandiari R, Torgue J, et al
    Targeted alpha-Emitter Therapy with (212)Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.
    J Nucl Med. 2022;63:1326-1333.
    PubMed     Abstract available


  394. COSTA PF, Fendler WP, Herrmann K, Sandach P, et al
    Radiation Protection and Occupational Exposure on (68)Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy.
    J Nucl Med. 2022;63:1349-1356.
    PubMed     Abstract available


    August 2022
  395. LAFOREST R, Ghai A, Fraum TJ, Oyama R, et al
    First-in-Human Evaluation of Safety and Dosimetry of (64)Cu-LLP2A for PET Imaging.
    J Nucl Med. 2022 Aug 25. pii: jnumed.122.264349. doi: 10.2967/jnumed.122.264349.
    PubMed     Abstract available


  396. PATHMANANDAVEL S, Crumbaker M, Ho B, Yam AO, et al
    Evaluation of (177)Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective (177)Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
    J Nucl Med. 2022 Aug 25. pii: jnumed.122.264398. doi: 10.2967/jnumed.122.264398.
    PubMed     Abstract available


  397. SILVA-RODRIGUEZ J, Labrador-Espinosa MA, Moscoso A, Scholl M, et al
    Differential effects of tau stage, Lewy body pathology, and substantia nigra degeneration on FDG-PET patterns in clinical AD.
    J Nucl Med. 2022 Aug 25. pii: jnumed.122.264213. doi: 10.2967/jnumed.122.264213.
    PubMed     Abstract available


  398. HAGENS MJ, Oprea-Lager DE, Vis AN, Wondergem M, et al
    Reproducibility of PSMA PET/CT Imaging for primary staging of treatment-naive prostate cancer patients depends on the applied radiotracer: a retrospective study.
    J Nucl Med. 2022 Aug 25. pii: jnumed.121.263139. doi: 10.2967/jnumed.121.263139.
    PubMed     Abstract available


  399. SHIN J, Parker MFL, Zhu I, Alanizi A, et al
    Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264284. doi: 10.2967/jnumed.122.264284.
    PubMed     Abstract available


  400. CARLSEN EA, Loft M, Loft A, Czyzewska D, et al
    Prospective phase II trial of [(68)Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT imaging of integrin alphavbeta3 for prognostication in patients with neuroendocrine neoplasms.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264383. doi: 10.2967/jnumed.122.264383.
    PubMed     Abstract available


  401. KERSTING D, Jentzen W, Jeronim D, Mavroeidi IA, et al
    Lesion Quantification Accuracy of Digital (90)Y PET Imaging in the Context of Dosimetry in Systemic FAPI Radionuclide Therapy.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264338. doi: 10.2967/jnumed.122.264338.
    PubMed     Abstract available


  402. EVANGELOU P, Omrane MA, Thurow J, Mix M, et al
    (68)Ga-DOTA Positron Emission Tomography for Diagnosis of Spinal Cerebrospinal Fluid Leaks.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264059. doi: 10.2967/jnumed.122.264059.
    PubMed     Abstract available


  403. BEYER T, Czernin J, Freudenberg LS, Giesel F, et al
    A 2022 INTERNATIONAL SURVEY ON THE STATUS OF PROSTATE CANCER THERANOSTICS.
    J Nucl Med. 2022 Aug 11. pii: jnumed.122.264298. doi: 10.2967/jnumed.122.264298.
    PubMed     Abstract available



  404. Cherry Receives 2022 Benedict Cassen Prize.
    J Nucl Med. 2022;63:10N.
    PubMed    


  405. KMETYUK Y, Czernin J, Herrmann K
    Practicing Medicine in Wartime Ukraine: A Conversation Between Yaroslav Kmetyuk, Johannes Czernin, and Ken Herrmann.
    J Nucl Med. 2022;63:1127-1130.
    PubMed    



  406. Schwaiger Recognized with de Hevesy Nuclear Pioneer Award.
    J Nucl Med. 2022;63:12N.
    PubMed    



  407. Mach Honored with SNMMI 2022 Paul C. Aebersold Award.
    J Nucl Med. 2022;63:13N.
    PubMed    



  408. JNM Impact Factor Rises Again.
    J Nucl Med. 2022;63:18N.
    PubMed    



  409. Science at the SNMMI Annual Meeting.
    J Nucl Med. 2022;63:19N-20N.
    PubMed    



  410. SNMMI Newsline.
    J Nucl Med. 2022;63:9N-20N.
    PubMed    


  411. PAPPAS V
    SNMMI Leadership Update: SNMMI 2022 Annual Meeting-In Person at Last.
    J Nucl Med. 2022;63:15N.
    PubMed    


  412. GONZALEZ-MONTORO A, Ullah MN, Levin CS
    Advances in Detector Instrumentation for PET.
    J Nucl Med. 2022;63:1138-1144.
    PubMed     Abstract available


  413. LEE JH, Simeon FG, Liow JS, Morse CL, et al
    In Vivo Evaluation of 6 Analogs of (11)C-ER176 as Candidate (18)F-Labeled Radioligands for 18-kDa Translocator Protein.
    J Nucl Med. 2022;63:1252-1258.
    PubMed     Abstract available


  414. BOULEAU A, Nozach H, Dubois S, Kereselidze D, et al
    Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of (89)Zr-Labeled Anti-PD-L1 Antibody Formats.
    J Nucl Med. 2022;63:1259-1265.
    PubMed     Abstract available


    July 2022
  415. LANG M, Spektor AM, Hielscher T, Hoppner J, et al
    Static and dynamic (68)Ga-FAPI PET/CT for the detection of malignant transformation of intraductal papillary mucinous neoplasia of the pancreas.
    J Nucl Med. 2022 Jul 29. pii: jnumed.122.264361. doi: 10.2967/jnumed.122.264361.
    PubMed     Abstract available


  416. GUEDJ E, Horowitz T
    Brain Metabolic PET Findings on the Long-Term Effects of COVID-19.
    J Nucl Med. 2022 Jul 29. pii: jnumed.122.264179. doi: 10.2967/jnumed.122.264179.
    PubMed    


  417. RUDDY TD, Al-Mallah M, Arrighi JA, Bois JP, et al
    SNMMI/ACR/ASNC/SCMR Joint Credentialing Statement for Cardiac PET/MRI.
    J Nucl Med. 2022 Jul 19. pii: jnumed.122.264200. doi: 10.2967/jnumed.122.264200.
    PubMed    


  418. SEIBYL JP
    Alpha-synuclein PET and Parkinson's Disease Therapeutic Trials: Ever the Twain Shall Meet?
    J Nucl Med. 2022 Jul 19. pii: jnumed.122.263918. doi: 10.2967/jnumed.122.263918.
    PubMed     Abstract available


  419. GEORGI TW, Stoevesandt D, Kurch L, Bartelt JM, et al
    Optimized whole-body positron emission tomography magnetic resonance imaging sequence workflow in pediatric Hodgkin lymphoma patients.
    J Nucl Med. 2022 Jul 14. pii: jnumed.122.264112. doi: 10.2967/jnumed.122.264112.
    PubMed     Abstract available


  420. KOEHLER D, Sauer M, Klutmann S, Apostolova I, et al
    Feasibility of (99m)Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients.
    J Nucl Med. 2022 Jul 14. pii: jnumed.122.263892. doi: 10.2967/jnumed.122.263892.
    PubMed     Abstract available


  421. KIM MJ, Juarez Anaya F, Manly LS, Lee JH, et al
    Whole-body PET imaging in humans shows that (11)C-PS13 is selective for cyclooxygenase-1 and can measure the in vivo potency of nonsteroidal anti-inflammatory drugs.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264061. doi: 10.2967/jnumed.122.264061.
    PubMed     Abstract available


  422. ISHII K, Hanaoka K, Watanabe S, Morimoto-Ishikawa D, et al
    High-resolution silicon photomultiplier time-of-flight dedicated head PET system for clinical brain studies.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264080. doi: 10.2967/jnumed.122.264080.
    PubMed     Abstract available


  423. LI RG, Stenberg VY, Larsen RH
    A Novel Experimental Generator for Production of High Purity Lead-212 for Use in Radiopharmaceuticals.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264009. doi: 10.2967/jnumed.122.264009.
    PubMed     Abstract available


  424. HOFLING AA, Fotenos AF, Niu G, Fallah J, et al
    Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264299. doi: 10.2967/jnumed.122.264299.
    PubMed    



  425. SNMMI Image of the Year 2022: PET/CT Biomarker Predicts Post-MI Cardiac Remodeling.
    J Nucl Med. 2022;63:16N.
    PubMed    


  426. STENDAHL JC, Kwan JM, Pucar D, Sadeghi MM, et al
    Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging.
    J Nucl Med. 2022;63:986-994.
    PubMed     Abstract available



  427. New Officers for SNMMI and SNMMI-TS.
    J Nucl Med. 2022;63:17N-18N.
    PubMed    


  428. CZERNIN J, Adams T, Calais J
    More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging.
    J Nucl Med. 2022;63:969-970.
    PubMed    


  429. GHESANI M
    SNMMI Leadership Update: Opportunities for Growth in Nuclear Medicine and Molecular Imaging.
    J Nucl Med. 2022;63:20N.
    PubMed    


  430. SEGALL G
    Recognition of the ABNM by the NRC.
    J Nucl Med. 2022;63:19N.
    PubMed    



  431. SNMMI Newsline.
    J Nucl Med. 2022;63:15N-26N.
    PubMed    


  432. GRKOVSKI M, Modak S, Zanzonico PB, Carrasquillo JA, et al
    Biodistribution and Radiation Dosimetry of Intraperitoneally Administered (124)I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors.
    J Nucl Med. 2022;63:1094-1100.
    PubMed     Abstract available


  433. DRESSING A, Bormann T, Blazhenets G, Schroeter N, et al
    Neuropsychologic Profiles and Cerebral Glucose Metabolism in Neurocognitive Long COVID Syndrome.
    J Nucl Med. 2022;63:1058-1063.
    PubMed     Abstract available


    June 2022
  434. PARIHAR AS, Mhlanga J, Ronstrom C, Schmidt LR, et al
    Diagnostic accuracy of (99m)Tc-Sestamibi SPECT/CT for characterization of solid renal masses.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.264329. doi: 10.2967/jnumed.122.264329.
    PubMed     Abstract available


  435. SHIYAM SUNDAR LK, Yu J, Muzik O, Kulterer O, et al
    Fully-automated, semantic segmentation of whole-body (18)F-FDG PET/CT images based on data-centric artificial intelligence.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.264063. doi: 10.2967/jnumed.122.264063.
    PubMed     Abstract available


  436. WAKABAYASHI Y, Strenkona P, Arakawa R, Yan X, et al
    First-in-human evaluation of (18)F-PF-06445974, a PET radioligand that preferentially labels phosphodiesterase-4B.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.263838. doi: 10.2967/jnumed.122.263838.
    PubMed     Abstract available


  437. ZHOU R, Choi H, Cao J, Pantel A, et al
    (18)F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.264152. doi: 10.2967/jnumed.122.264152.
    PubMed     Abstract available


  438. PATHMANANDAVEL S, Crumbaker M, Nguyen A, Yam AOW, et al
    The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with (177)LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
    J Nucl Med. 2022 Jun 23. pii: jnumed.122.264104. doi: 10.2967/jnumed.122.264104.
    PubMed     Abstract available


  439. LE TM, Lee HR, Abt ER, Rashid K, et al
    (18)F-FDG PET visualizes systemic STING agonist-induced lymphocyte activation in preclinical models.
    J Nucl Med. 2022 Jun 23. pii: jnumed.122.264121. doi: 10.2967/jnumed.122.264121.
    PubMed     Abstract available


  440. ZHENG KH, Kroon J, Schoormans J, Gurney-Champion O, et al
    (89)Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.
    J Nucl Med. 2022 Jun 23. pii: jnumed.121.263330. doi: 10.2967/jnumed.121.263330.
    PubMed     Abstract available


  441. REICHKENDLER M, Andersen FL, Borgwardt L, Nygaard U, et al
    Long axial field of view with 5 min acquisition time enables PET/CT in toddler without sedation.
    J Nucl Med. 2022 Jun 16. pii: jnumed.121.263626. doi: 10.2967/jnumed.121.263626.
    PubMed    


  442. NITSCHE C, Mascherbauer K, Calabretta R, Koschutnik M, et al
    Prevalence and outcomes of cardiac amyloidosis in all-comer referrals for bone scintigraphy.
    J Nucl Med. 2022 Jun 16. pii: jnumed.122.264041. doi: 10.2967/jnumed.122.264041.
    PubMed     Abstract available


  443. GIRUM KB, Rebaud L, Cottereau AS, Meignan M, et al
    (18)F-FDG PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients.
    J Nucl Med. 2022 Jun 16. pii: jnumed.121.263501. doi: 10.2967/jnumed.121.263501.
    PubMed     Abstract available


  444. ANTONI G, Lubberink M, Sorensen J, Lindstrom E, et al
    In Vivo Visualization and Quantification of Neutrophil Elastase in Lungs of COVID-19 Patients - A First-In-Human Positron Emission Tomography Study with (11)C-GW457427.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.263974. doi: 10.2967/jnumed.122.263974.
    PubMed     Abstract available


  445. SIEBINGA H, Olde Heuvel J, Rijkhorst EJ, Hendrikx JJMA, et al
    The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on (68)Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264101. doi: 10.2967/jnumed.122.264101.
    PubMed     Abstract available


  446. POMYKALA KL, Herrmann K, Padhani AR, Hofman MS, et al
    Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Prostate Cancer: We have the answers.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264394. doi: 10.2967/jnumed.122.264394.
    PubMed    


  447. STERBIS E, Liang R, Trivedi P, Kwak J, et al
    Lack of adherence to guideline-based imaging prior to subsequent radiation in patients with non-small cell lung cancer: Impact on patient outcomes.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264131. doi: 10.2967/jnumed.122.264131.
    PubMed     Abstract available


  448. AVRAM AM, Giovanella L, Greenspan B, Lawson SA, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.
    J Nucl Med. 2022;63:15N-35N.
    PubMed    


  449. MINOSHIMA S, Cross D, Thientunyakit T, Foster NL, et al
    (18)F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  450. CHAPLEAU M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD, et al
    The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  451. TIEPOLT S, Meyer PM, Patt M, Deuther-Conrad W, et al
    PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  452. GROOT C, Villeneuve S, Smith R, Hansson O, et al
    Tau PET Imaging in Neurodegenerative Disorders.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  453. KENOU BV, Manly LS, Rubovits SB, Umeozulu SA, et al
    Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia.
    J Nucl Med. 2022;63.
    PubMed     Abstract available



  454. SNMMI Newsline.
    J Nucl Med. 2022;63:13N-35N.
    PubMed    



  455. Outstanding JNMT Articles for 2021.
    J Nucl Med. 2022;63:13N.
    PubMed    


  456. WAHL RL
    SNMMI Leadership Update: Putting Patients First: A Year in Review.
    J Nucl Med. 2022;63:14N.
    PubMed    


  457. CARSON RE, Naganawa M, Toyonaga T, Koohsari S, et al
    Imaging of Synaptic Density in Neurodegenerative Disorders.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  458. MASDEU JC, Pascual B, Fujita M
    Imaging Neuroinflammation in Neurodegenerative Disorders.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  459. BARTHEL H, Villemagne VL, Drzezga A
    Future Directions in Molecular Imaging of Neurodegenerative Disorders.
    J Nucl Med. 2022;63.
    PubMed     Abstract available


  460. VILLEMAGNE VL, Barthel H
    Molecular Imaging of Neurodegeneration: The Way to New Horizons.
    J Nucl Med. 2022;63.
    PubMed    


  461. LEE ST, Emmett LM, Pattison DA, Hofman MS, et al
    The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective.
    J Nucl Med. 2022;63:819-822.
    PubMed     Abstract available


  462. WU M, Ning J, Li J, Lai Z, et al
    Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls.
    J Nucl Med. 2022;63:948-951.
    PubMed     Abstract available


  463. BERTOGLIO D, Verhaeghe J, Wyffels L, Miranda A, et al
    Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
    J Nucl Med. 2022;63:942-947.
    PubMed     Abstract available


  464. COUSINS MM, Devasia TP, Maurino CM, Mikell J, et al
    Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After (90)Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity.
    J Nucl Med. 2022;63:882-889.
    PubMed     Abstract available


    May 2022
  465. GLATTING FM, Hoppner J, Liew DP, van Genabith A, et al
    Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-74: methodological and diagnostic implications for malignant, inflammatory and degenerative lesions.
    J Nucl Med. 2022 May 26. pii: jnumed.122.264069. doi: 10.2967/jnumed.122.264069.
    PubMed     Abstract available


  466. SARTOR O
    Invited Perspective, Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis.
    J Nucl Med. 2022 May 26. pii: jnumed.122.264128. doi: 10.2967/jnumed.122.264128.
    PubMed    


  467. JHA AK, Bradshaw TJ, Buvat I, Hatt M, et al
    Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE guidelines).
    J Nucl Med. 2022 May 26. pii: jnumed.121.263239. doi: 10.2967/jnumed.121.263239.
    PubMed     Abstract available


  468. OUVRARD E, De Mestier L, Boursier C, Lachachi B, et al
    (18)F-Fluorodihydroxyphenylalanine PET/CT at the Forefront for Initial and/or Pre-surgical Evaluation of Small Intestine Neuroendocrine Tumors.
    J Nucl Med. 2022 May 19. pii: jnumed.122.263984. doi: 10.2967/jnumed.122.263984.
    PubMed     Abstract available


  469. LOFT M, Christensen C, Clausen MM, Carlsen EA, et al
    First-in-Human PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using (18)F-labeled Active-Site Inhibited Factor VII ((18)F-ASIS): Potential as Companion Diagnostic.
    J Nucl Med. 2022 May 19. pii: jnumed.122.264068. doi: 10.2967/jnumed.122.264068.
    PubMed     Abstract available


  470. LOVINFOSSE P, Ferreira M, Withofs N, Jadoul A, et al
    Distinction of lymphoma from sarcoidosis at FDG PET/CT - evaluation of radiomic-feature guided machine learning versus human reader performance.
    J Nucl Med. 2022 May 19. pii: jnumed.121.263598. doi: 10.2967/jnumed.121.263598.
    PubMed     Abstract available


  471. ABDELHAFEZ Y, Raychaudhuri SP, Mazza D, Sarkar S, et al
    Total-Body (18)F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations.
    J Nucl Med. 2022 May 19. pii: jnumed.121.263774. doi: 10.2967/jnumed.121.263774.
    PubMed     Abstract available


  472. BARTOS LM, Kunte ST, Beumers P, Xiang X, et al
    Single cell radiotracer allocation via immunomagentic sorting (scRadiotracing) to disentangle PET signals at cellular resolution.
    J Nucl Med. 2022 May 19. pii: jnumed.122.264171. doi: 10.2967/jnumed.122.264171.
    PubMed     Abstract available


  473. SUBRAMANIAM RM, Duan F, Romanoff J, Yu JQ, et al
    (18)F FDG PET/CT Staging of Head and Neck Cancer: Inter-observer agreement and accuracy - Results from multicenter ACRIN 6685 Clinical Trial.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263902. doi: 10.2967/jnumed.122.263902.
    PubMed     Abstract available


  474. DUAN H, Baratto L, Fan RE, Soerensen SJC, et al
    Correlation of (68)Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263971. doi: 10.2967/jnumed.122.263971.
    PubMed     Abstract available


  475. ERBA PA, Natali A, Strauss HW, Mariani G, et al
    Brown Adipose Tissue Activity Following Exposure to the Cold and [(18)F]FDG Uptake: from Possible Pitfall in Early PET Scans to Metabolic Biomarker.
    J Nucl Med. 2022 May 12. pii: jnumed.122.264188. doi: 10.2967/jnumed.122.264188.
    PubMed    


  476. VERHOEFF SR, van de Donk PP, Aarntzen EHJG, Oosting SF, et al
    (89)Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer.
    J Nucl Med. 2022 May 5. pii: jnumed.121.263470. doi: 10.2967/jnumed.121.263470.
    PubMed     Abstract available


  477. MORADI F, Duan H, Song H, Davidzon GA, et al
    (68)Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
    J Nucl Med. 2022 May 5. pii: jnumed.122.263897. doi: 10.2967/jnumed.122.263897.
    PubMed     Abstract available


  478. HOPE TA, Jadvar H
    Updates to Appropriate Use Criteria for PSMA PET.
    J Nucl Med. 2022;63:14N.
    PubMed    


  479. WAHL RL
    SNMMI Leadership Update: SNMMI's Role in the Nuclear Medicine Renaissance.
    J Nucl Med. 2022;63:16N-17N.
    PubMed    



  480. SNMMI Newsline.
    J Nucl Med. 2022;63:13N-24N.
    PubMed    



  481. ASNC/SNMMI Radionuclide Authorized User Training Course.
    J Nucl Med. 2022;63:15N.
    PubMed    


  482. STENDAHL JC, Kwan JM, Pucar D, Sadeghi MM, et al
    Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 1: Technical Considerations and Perfusion and Neuronal Imaging.
    J Nucl Med. 2022;63:649-658.
    PubMed     Abstract available


  483. SALAS JR, Clark PM
    Signaling Pathways That Drive (18)F-FDG Accumulation in Cancer.
    J Nucl Med. 2022;63:659-663.
    PubMed     Abstract available


  484. TAMBORINO G, Perrot Y, De Saint-Hubert M, Struelens L, et al
    Modeling Early Radiation DNA Damage Occurring During (177)Lu-DOTATATE Radionuclide Therapy.
    J Nucl Med. 2022;63:761-769.
    PubMed     Abstract available


  485. ERIKSSON O, Velikyan I, Haack T, Bossart M, et al
    Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.
    J Nucl Med. 2022;63:794-800.
    PubMed     Abstract available


  486. HANSCHEID H, Schirbel A, Hartrampf P, Kraus S, et al
    Biokinetics and Dosimetry of (177)Lu-Pentixather.
    J Nucl Med. 2022;63:754-760.
    PubMed     Abstract available


  487. FERDINANDUS J, Costa PF, Kessler L, Weber M, et al
    Initial Clinical Experience with (90)Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients.
    J Nucl Med. 2022;63:727-734.
    PubMed     Abstract available


    April 2022
  488. BROOKS AL, Winton W, Stauff J, Arteaga J, et al
    Development of Flourinated NP-59: A Revival of Cholesterol Utilization Imaging with PET.
    J Nucl Med. 2022 Apr 28. pii: jnumed.122.263864. doi: 10.2967/jnumed.122.263864.
    PubMed     Abstract available


  489. KUNIHIRO AG, Sarrett SM, Lastwika KJ, Solan JL, et al
    CD133 as a Biomarker for an Autoantibody-to-ImmunoPET Paradigm for the Early Detection of Small Cell Lung Cancer.
    J Nucl Med. 2022 Apr 28. pii: jnumed.121.263511. doi: 10.2967/jnumed.121.263511.
    PubMed     Abstract available


  490. DENIS CES, Cousin FC, De Laere B, Hustinx R, et al
    Using, (68)Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
    J Nucl Med. 2022 Apr 21. pii: jnumed.121.263611. doi: 10.2967/jnumed.121.263611.
    PubMed     Abstract available


  491. CHERK MH, Khor R, Barber TW, Yap KSK, et al
    Non-Invasive Assessment of Acute Graft vs. Host Disease of the Gastrointestinal Tract Following Allogeneic Haemopoietic Stem Cell Transplantation Using (18)F-FDG PET.
    J Nucl Med. 2022 Apr 21. pii: jnumed.121.263688. doi: 10.2967/jnumed.121.263688.
    PubMed     Abstract available


  492. PIRASTEH A, Periyasamy S, Meudt JJ, Lui Y, et al
    Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor Positron Emission Tomography in a Human-sized Swine Model.
    J Nucl Med. 2022 Apr 21. pii: jnumed.121.263736. doi: 10.2967/jnumed.121.263736.
    PubMed     Abstract available


  493. BROER LN, Knapen DG, Suurs FV, Moen I, et al
    (89)Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted (227)Th-conjugate therapy in mice.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.263079. doi: 10.2967/jnumed.121.263079.
    PubMed     Abstract available


  494. ROTH KS, Voltin CA, van-Heek L, Wegen S, et al
    Dual-tracer PET/CT protocol with [(18)F]-FDG and [(68)Ga]Ga-FAPI-46 for cancer imaging - a proof of concept.
    J Nucl Med. 2022 Apr 14. pii: jnumed.122.263835. doi: 10.2967/jnumed.122.263835.
    PubMed     Abstract available


  495. DEWARAJA YK, Mirando DM, Peterson A, Niedbala J, et al
    A pipeline for automated voxel dosimetry: application in patients with multi-SPECT/CT imaging following (177)Lu peptide receptor radionuclide therapy.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.263738. doi: 10.2967/jnumed.121.263738.
    PubMed     Abstract available


  496. MESSERSCHMIDT K, Barthel H, Brendel M, Scherlach C, et al
    (18)F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.262854. doi: 10.2967/jnumed.121.262854.
    PubMed     Abstract available


  497. ROSEN J, Ceccon G, Bauer EK, Werner JM, et al
    Cost-effectiveness of (18)F-FET PET for early treatment response assessment in glioma patients following adjuvant temozolomide chemotherapy.
    J Nucl Med. 2022 Apr 14. pii: jnumed.122.263790. doi: 10.2967/jnumed.122.263790.
    PubMed     Abstract available


  498. GAFITA A, Rauscher I, Weber M, Hadaschik B, et al
    Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.263072. doi: 10.2967/jnumed.121.263072.
    PubMed     Abstract available


  499. KUWERT T, Schmidkonz C, Prante O, Schett G, et al
    FAPI-PET Opens a New Window for Understanding of Immune-Mediated Inflammatory Diseases.
    J Nucl Med. 2022 Apr 7. pii: jnumed.122.263922. doi: 10.2967/jnumed.122.263922.
    PubMed     Abstract available


  500. KROENKE M, Schweiger L, Horn T, Haller B, et al
    Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2022 Apr 7. pii: jnumed.121.263707. doi: 10.2967/jnumed.121.263707.
    PubMed     Abstract available


  501. GORDON L
    ABNM: Nuclear Medicine In-Training Examination Goes Virtual.
    J Nucl Med. 2022;63:18N.
    PubMed    



  502. SNMMI Calls for Expanded Coverage/Reimbursement of Amyloid PET.
    J Nucl Med. 2022;63:17N.
    PubMed    


  503. PAPPAS V
    SNMMI Leadership Update: SNMMI Meetings Back in Full Swing.
    J Nucl Med. 2022;63:19N.
    PubMed    



  504. SNMMI Newsline.
    J Nucl Med. 2022;63:15N-26N.
    PubMed    


  505. NELSON BJB, Ferguson S, Wuest M, Wilson J, et al
    First In Vivo and Phantom Imaging of Cyclotron-Produced (133)La as a Theranostic Radionuclide for (225)Ac and (135)La.
    J Nucl Med. 2022;63:584-590.
    PubMed     Abstract available


    March 2022
  506. EMMETT LM, Papa N, Buteau J, Ho B, et al
    The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.
    J Nucl Med. 2022 Mar 17. pii: jnumed.121.263448. doi: 10.2967/jnumed.121.263448.
    PubMed     Abstract available


  507. LEE J, Burkett BJ, Min HK, Lundt ES, et al
    The Overlap Index as a means of evaluating early tau-PET signal reliability.
    J Nucl Med. 2022 Mar 17. pii: jnumed.121.263136. doi: 10.2967/jnumed.121.263136.
    PubMed     Abstract available


  508. ZARAGORI T, Verger A
    Reply to Letter to the Editor: "(18)F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study".
    J Nucl Med. 2022 Mar 17. pii: jnumed.122.264035. doi: 10.2967/jnumed.122.264035.
    PubMed    


  509. HOTTA M, Gafita A, Czernin J, Calais J, et al
    Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with (177)Lu-PSMA therapy: a multicenter retrospective analysis.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.263441. doi: 10.2967/jnumed.121.263441.
    PubMed     Abstract available


  510. ILHAN H, Kroenke M, Wurzer A, Unterrainer M, et al
    (18)F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.262861. doi: 10.2967/jnumed.121.262861.
    PubMed     Abstract available


  511. SUILAMO S, Li XG, Lankinen P, Oikonen V, et al
    (68)Ga-Citrate Positron Emission Tomography of Healthy Men: Whole-Body Biodistribution Kinetics and Radiation Dose Estimates.
    J Nucl Med. 2022 Mar 10. pii: jnumed.122.263884. doi: 10.2967/jnumed.122.263884.
    PubMed     Abstract available


  512. FONTI R, Panico M, Pellegrino S, Pulcrano A, et al
    Heterogeneity of SSTR2 expression assessed by (68)Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.262928. doi: 10.2967/jnumed.121.262928.
    PubMed     Abstract available


  513. PANTEL AR, Mankoff DA, Karp JS
    Total Body PET - Will it Change Science and Practice?
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.263481. doi: 10.2967/jnumed.121.263481.
    PubMed    


  514. NOTOHAMIPRODJO S, Eiber M, Lohrmann C, Weber WA, et al
    Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on (18)F-rhPSMA-7.3 PET/CT in patients with prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263758. doi: 10.2967/jnumed.121.263758.
    PubMed     Abstract available


  515. BUCK AK, Haug A, Dreher N, Lambertini A, et al
    Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using (68)Ga-PentixaFor PET.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263693. doi: 10.2967/jnumed.121.263693.
    PubMed     Abstract available


  516. GONDOPUTRO W, Scheltema MJ, Blazevski A, Doan P, et al
    Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263743. doi: 10.2967/jnumed.121.263743.
    PubMed     Abstract available



  517. SNMMI Launches Radiopharmaceutical Therapy Centers of Excellence Program.
    J Nucl Med. 2022;63:14N.
    PubMed    


  518. PRASAD V, Boss M, Rottenburger C, Brenner W, et al
    Reply: (68)Ga NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
    J Nucl Med. 2022;63:493-494.
    PubMed    


  519. BANERJEE I, Sajjan R, Estebanez MS, Dunne MJ, et al
    (68)Ga-NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
    J Nucl Med. 2022;63:493.
    PubMed    


  520. GULUDEC DL, Czernin J, Calais J
    Health Care and Nuclear Medicine in France: A Conversation Between Dominique Le Guludec, Johannes Czernin, and Jeremie Calais.
    J Nucl Med. 2022;63:327-330.
    PubMed    


  521. TZOLOS E, Kwiecinski J, Berman D, Slomka P, et al
    Latest Advances in Multimodality Imaging of Aortic Stenosis.
    J Nucl Med. 2022;63:353-358.
    PubMed     Abstract available


  522. SARI H, Reaungamornrat J, Catalano OA, Vera-Olmos J, et al
    Evaluation of Deep Learning-Based Approaches to Segment Bowel Air Pockets and Generate Pelvic Attenuation Maps from CAIPIRINHA-Accelerated Dixon MR Images.
    J Nucl Med. 2022;63:468-475.
    PubMed     Abstract available


  523. DING J, Tong A, Zhang Y, Wen J, et al
    Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using (68)Ga-Pentixafor.
    J Nucl Med. 2022;63:368-375.
    PubMed     Abstract available


  524. ROTH D, Gustafsson J, Warfvinge CF, Sundlov A, et al
    Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with (177)Lu-DOTATATE.
    J Nucl Med. 2022;63:399-405.
    PubMed     Abstract available


  525. EERTINK JJ, Pfaehler EAG, Wiegers SE, van T, et al
    Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?
    J Nucl Med. 2022;63:389-395.
    PubMed     Abstract available


  526. LASSEN ML, Byrne C, Sheykhzade M, Wissenberg M, et al
    Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia.
    J Nucl Med. 2022;63:431-437.
    PubMed     Abstract available


  527. VIRGOLINI I, Bahri S, Kjaer A, Gronbaek H, et al
    A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for (68)Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    J Nucl Med. 2022;63:376-383.
    PubMed     Abstract available


  528. BAUM RP, Schuchardt C, Singh A, Chantadisai M, et al
    Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using (177)Lu-FAP-2286: First-in-Humans Results.
    J Nucl Med. 2022;63:415-423.
    PubMed     Abstract available


  529. WAHL RL
    SNMMI Leadership Update: Call the Nuclear Oncologist.
    J Nucl Med. 2022;63:15N.
    PubMed    



  530. SNMMI Statement: Possible Effect of Omicron Infection on (18)F-FDG-Based Imaging.
    J Nucl Med. 2022;63:11N.
    PubMed    



  531. SNMMI Newsline.
    J Nucl Med. 2022;63:11N-22N.
    PubMed    


    February 2022
  532. LEITHNER D, Schoder H, Haug AR, Vargas HA, et al
    Impact of ComBat harmonization on PET radiomics-based tissue classification: a dual-center PET/MR and PET/CT study.
    J Nucl Med. 2022 Feb 24. pii: jnumed.121.263102. doi: 10.2967/jnumed.121.263102.
    PubMed     Abstract available


  533. YANG Z, Li F, Huang Y, Yin N, et al
    Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma.
    J Nucl Med. 2022 Feb 24. pii: jnumed.121.263151. doi: 10.2967/jnumed.121.263151.
    PubMed     Abstract available


  534. DIEKMANN J, Koenig T, Thackeray JT, Derlin T, et al
    Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with Magnetic Resonance Tissue Characterization and Subsequent Functional Outcome.
    J Nucl Med. 2022 Feb 24. pii: jnumed.121.263555. doi: 10.2967/jnumed.121.263555.
    PubMed     Abstract available


  535. LUCOT KL, Stevens MY, Bonham TA, Azevedo EC, et al
    TRACKING INNATE IMMUNE ACTIVATION IN A MOUSE MODEL OF PARKINSON'S DISEASE USING TREM1 AND TSPO PET TRACERS.
    J Nucl Med. 2022 Feb 17. pii: jnumed.121.263039. doi: 10.2967/jnumed.121.263039.
    PubMed     Abstract available


  536. WU WY, Yu F, Zhang PJ, Bu T, et al
    (68)Ga-DOTA-NT-20.3 Neurotensin receptor 1 positron emission tomography imaging as a surrogate for neuroendocrine differentiation of prostate cancer.
    J Nucl Med. 2022 Feb 17. pii: jnumed.121.263132. doi: 10.2967/jnumed.121.263132.
    PubMed     Abstract available


  537. FORAY C, Barca C, Winkeler A, Wagner S, et al
    Interrogating glioma-associated microglia/macrophage dynamics under CSF-1R therapy with multi-tracer in vivo PET/MR imaging.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263318. doi: 10.2967/jnumed.121.263318.
    PubMed     Abstract available


  538. BARCA C, Kiliaan AJ, Wachsmuth L, Foray C, et al
    Short-term colony stimulating factor-1 receptor inhibition-induced repopulation after stroke assessed by longitudinal (18)F-DPA-714 PET imaging.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263004. doi: 10.2967/jnumed.121.263004.
    PubMed     Abstract available


  539. ZHANG X, Li M, Gai Y, Chen J, et al
    (18)F-PFPN PET: a new and attractive imaging modality for patients with malignant melanoma.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263179. doi: 10.2967/jnumed.121.263179.
    PubMed     Abstract available


  540. ZANOTTI-FREGONARA P, Ishiguro T, Yoshihara K, Ishii S, et al
    (18)F-FDG Fetal Dosimetry Calculated with PET/MRI.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263561. doi: 10.2967/jnumed.121.263561.
    PubMed     Abstract available



  541. FDA Approves New (68)Ga Kit for Prostate Cancer PET.
    J Nucl Med. 2022;63:26N.
    PubMed    


  542. WAHL RL
    SNMMI to Host Summits on Artificial Intelligence and Patient Access.
    J Nucl Med. 2022;63:27N.
    PubMed    


  543. ZIDAN L, Iravani A, Oleinikov K, Ben-Haim S, et al
    Efficacy and Safety of (177)Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.
    J Nucl Med. 2022;63:218-225.
    PubMed     Abstract available


  544. GILLESSEN S, Czernin J, Herrmann K
    A European Oncology Leader Looks at PSMA: A Conversation Between Silke Gillessen, Johannes Czernin, and Ken Herrmann.
    J Nucl Med. 2022;63:169-171.
    PubMed    


  545. ORLHAC F, Eertink JJ, Cottereau AS, Zijlstra JM, et al
    A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies.
    J Nucl Med. 2022;63:172-179.
    PubMed     Abstract available


  546. KHODAII J, Araj-Khodaei M, Vafaee MS, Wong DF, et al
    Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots.
    J Nucl Med. 2022;63:294-301.
    PubMed     Abstract available


  547. ZHANG Y, Kupferschlaeger J, Lang P, Reischl G, et al
    (131)I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors.
    J Nucl Med. 2022;63:205-211.
    PubMed     Abstract available


    January 2022
  548. VILEMAGNE VL, Harada R, Dore V, Furumoto S, et al
    First-in-human evaluation of (18)F-SMBT-1, a novel (18)F-labeled MAO-B PET tracer for imaging reactive astrogliosis.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263254. doi: 10.2967/jnumed.121.263254.
    PubMed     Abstract available


  549. ALBERGE JB, Kraeber-Bodere F, Jamet B, Touzeau C, et al
    Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.262884. doi: 10.2967/jnumed.121.262884.
    PubMed     Abstract available


  550. SPANGLER-BICKELL MG, Hurley SA, Pirasteh A, Perlman SB, et al
    Evaluation of Data-Driven Rigid Motion Correction in Clinical Brain PET Imaging.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263309. doi: 10.2967/jnumed.121.263309.
    PubMed     Abstract available


  551. KUO PH, Benson T, Messmann R, Groaning M, et al
    Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263638. doi: 10.2967/jnumed.121.263638.
    PubMed    


  552. SEO M, Kim Y, Ye BD, Park SH, et al
    Positron emission tomography imaging of system xc(-) in immune cells for assessment of disease activity in mice and patients with inflammatory bowel disease.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263289. doi: 10.2967/jnumed.121.263289.
    PubMed     Abstract available


  553. LANGEN KJ, Mottaghy FM
    Letter to the Editor: "(18)F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study" [J Nucl Med 2022; 63:147-157].
    J Nucl Med. 2022 Jan 27. pii: jnumed.122.263837. doi: 10.2967/jnumed.122.263837.
    PubMed    


  554. WESTDORP H, Verhoeff SR, Gotthardt M, van Herpen CML, et al
    Towards a better understanding of immune checkpoint inhibitor radiolabeled PET imaging studies.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.262622. doi: 10.2967/jnumed.121.262622.
    PubMed    


  555. NG M, Guerrieri M, Wong LM, Taubman K, et al
    The change in management by (18)F-DCFPyL PSMA PET scanning in patients undergoing post-prostatectomy radiotherapy, with early biochemical response outcomes.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263521. doi: 10.2967/jnumed.121.263521.
    PubMed     Abstract available


  556. CARLSEN EA, Loft M, Loft A, Berthelsen AK, et al
    Prospective phase II trial of prognostication by (68)Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263177. doi: 10.2967/jnumed.121.263177.
    PubMed     Abstract available


  557. BUNNING S, Ignace C, Mattmuller S, Schwarz SW, et al
    Proceedings: PET Drugs: A Workshop on Inspections Management and Regulatory Considerations.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263443. doi: 10.2967/jnumed.121.263443.
    PubMed     Abstract available


  558. KORSEN JA, Kalidindi TM, Khitrov S, Samuels ZV, et al
    Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263221. doi: 10.2967/jnumed.121.263221.
    PubMed     Abstract available


  559. PRIVE BM, Peters S, Uijen MJM, Janssen MJR, et al
    Letter to the Editor RE: Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
    J Nucl Med. 2022 Jan 13. pii: jnumed.122.263802. doi: 10.2967/jnumed.122.263802.
    PubMed    


  560. BERTOGLIO D, Halloin N, De Lombaerde S, Jankovski A, et al
    SV2A PET imaging is a non-invasive marker for the detection of spinal damages in experimental models of spinal cord injury.
    J Nucl Med. 2022 Jan 13. pii: jnumed.121.263222. doi: 10.2967/jnumed.121.263222.
    PubMed     Abstract available


  561. LANGBEIN T, Wang H, Rauscher I, Kronke M, et al
    Utility of (18)F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
    J Nucl Med. 2022 Jan 6. pii: jnumed.121.263440. doi: 10.2967/jnumed.121.263440.
    PubMed     Abstract available


  562. DRIESSEN J, Zwezerijnen GJ, Schoder H, Drees EE, et al
    The impact of semi-automatic segmentation methods on metabolic tumor volume, intensity and dissemination radiomics in (18)F-FDG PET scans of patients with classical Hodgkin lymphoma.
    J Nucl Med. 2022 Jan 6. pii: jnumed.121.263067. doi: 10.2967/jnumed.121.263067.
    PubMed     Abstract available


  563. WAHL RL
    Ensuring Quality and Safety in Nuclear Medicine Imaging and Therapy.
    J Nucl Med. 2022;63:18N.
    PubMed    


  564. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:69-75.
    PubMed     Abstract available


  565. HICKS R, Czernin J, Herrmann K
    Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann.
    J Nucl Med. 2022;63:1-4.
    PubMed    


    December 2021
  566. KOLINGER GD, Vallez Garcia D, Kramer GM, Frings V, et al
    Effects of tracer uptake time in non-small cell lung cancer (18)F-FDG PET radiomics.
    J Nucl Med. 2021 Dec 21. pii: jnumed.121.262660. doi: 10.2967/jnumed.121.262660.
    PubMed     Abstract available


  567. LI E, Spencer BA, Schmall JP, Abdelhafez Y, et al
    Efficient delay correction for total-body PET kinetic modeling using pulse timing methods.
    J Nucl Med. 2021 Dec 21. pii: jnumed.121.262968. doi: 10.2967/jnumed.121.262968.
    PubMed     Abstract available


  568. CHOI YJ, Koh Y, Lee HJ, Hwang IC, et al
    Independent Prognostic Utility of (11)C-Pittsburgh Compound B Positron Emission Tomography in Light-Chain Cardiac Amyloidosis Patients.
    J Nucl Med. 2021 Dec 16. pii: jnumed.121.263033. doi: 10.2967/jnumed.121.263033.
    PubMed     Abstract available


  569. MENA E, Rowe SP, Shih JH, Lindenberg L, et al
    Predictors of (18)F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
    J Nucl Med. 2021 Dec 16. pii: jnumed.121.262347. doi: 10.2967/jnumed.121.262347.
    PubMed     Abstract available


  570. ZEYDAN B, Schwarz CG, Przybelski SA, Lesnick TG, et al
    Comparison of (11)C-Pittsburgh compound-B and (18)F-Flutemetamol White Matter Binding in PET.
    J Nucl Med. 2021 Dec 16. pii: jnumed.121.263281. doi: 10.2967/jnumed.121.263281.
    PubMed     Abstract available


  571. LI C, Han C, Duan S, Li P, et al
    Visualizing T cell responses: The T cell PET imaging toolbox.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.261976. doi: 10.2967/jnumed.121.261976.
    PubMed     Abstract available


  572. FRIEDMAN NC
    The Will Rodgers Phenomenon and PSMA PET/CT.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.263556. doi: 10.2967/jnumed.121.263556.
    PubMed    


  573. CREFF G, Jegoux F, Palard-Novello X, Depeursinge A, et al
    FDG-PET/CT-based prognostic survival model after surgery for head and neck cancer.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262891. doi: 10.2967/jnumed.121.262891.
    PubMed     Abstract available


  574. SCHUCHARDT C, Zhang J, Kulkarni HR, Chen X, et al
    Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262713. doi: 10.2967/jnumed.121.262713.
    PubMed     Abstract available


  575. SEBAN RD, Richard C, Nascimento-Leite C, Ghidaglia J, et al
    Absolute lymphocyte count after COVID-19 vaccination is associated with vaccine-induced hypermetabolic lymph nodes on (18)F-FDG PET/CT: a focus in breast cancer care.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.263082. doi: 10.2967/jnumed.121.263082.
    PubMed     Abstract available


  576. MORTIMER JE, Bading JR, Frankel PH, Caroll M, et al
    Use of (64)Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262940. doi: 10.2967/jnumed.121.262940.
    PubMed     Abstract available


  577. BOUDOUSQ V, Guignard N, Gilly O, Chambert B, et al
    Diagnostic performances of cervical ultrasound, sestamibi scintigraphy and contrast-enhanced (18)F-fluorocholine positron emission tomography in primary hyperparathyroidism.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.261900. doi: 10.2967/jnumed.121.261900.
    PubMed     Abstract available


  578. RISOER LM, Clausen MM, Ujmajuridze Z, Farhadi M, et al
    Prognostic value of Urokinase-type Plasminogen Activator Receptor (uPAR)-PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with (18)F-FDG-PET/CT: A single-center prospective study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262866. doi: 10.2967/jnumed.121.262866.
    PubMed     Abstract available


  579. BARRINGTON SF, Mir F, El-Galaly TC, Knapp A, et al
    Follicular lymphoma treated with first-line immunochemotherapy: a review of PET-CT in patients who did not achieve CMR in the GALLIUM study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262869. doi: 10.2967/jnumed.121.262869.
    PubMed     Abstract available


  580. PROMTEANGTRONG C, Siripongsatian D, Jantarato A, Kunawudhi A, et al
    Head-to-head comparison of (68)Ga-FAPI-46 and (18)F-FDG PET/CT for evaluation of head and neck squamous cell carcinoma: a single-center exploratory study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262831. doi: 10.2967/jnumed.121.262831.
    PubMed     Abstract available


  581. LASSMANN M, Eberlein U, Gear J, Konijnenberg M, et al
    Dosimetry for Radiopharmaceutical Therapy: The European Perspective.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  582. PANDIT-TASKAR N, Iravani A, Lee D, Jacene H, et al
    Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  583. GRAVES SA, Bageac A, Crowley JR, Merlino DAM, et al
    Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  584. CAPALA J, Graves SA, Scott A, Sgouros G, et al
    Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  585. WAHL RL, Sgouros G, Iravani A, Jacene H, et al
    Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns.
    J Nucl Med. 2021;62.
    PubMed    


  586. WAHL RL, Sunderland J
    Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice.
    J Nucl Med. 2021;62.
    PubMed    


  587. SGOUROS G, Dewaraja YK, Escorcia F, Graves SA, et al
    Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  588. URIBE C, Peterson A, Van B, Fedrigo R, et al
    An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and Early Results of the SNMMI Dosimetry Challenge.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


    November 2021
  589. COSTA GCA, Spencer BA, Omidvari N, Foster C, et al
    Radioembolization Dosimetry with Total-Body (90)Y PET.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.263145. doi: 10.2967/jnumed.121.263145.
    PubMed     Abstract available


  590. WANG G, Nardo L, Parikh M, Abdelhafez YG, et al
    Total-Body PET Multiparametric Imaging of Cancer Using a Voxel-wise Strategy of Compartmental Modeling.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.262668. doi: 10.2967/jnumed.121.262668.
    PubMed     Abstract available


  591. MALPETTI M, Kaalund SS, Tsvetanov KA, Rittman T, et al
    In vivo (18)F-flortaucipir PET does not accurately support the staging of progressive supranuclear palsy.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.262985. doi: 10.2967/jnumed.121.262985.
    PubMed     Abstract available


  592. THEISEN AL, Lassmann M, Tran-Gia J
    Towards a patient-specific traceable quantification of SPECT/CT-based radiopharmaceutical distributions.
    J Nucl Med. 2021 Nov 18. pii: jnumed.121.262925. doi: 10.2967/jnumed.121.262925.
    PubMed     Abstract available


  593. REDDY RP, Schmidtlein CR, Giancipoli RG, Mauguen A, et al
    The quest for an accurate functional tumor volume with (68)Ga-DOTATATE PET/CT.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.262782. doi: 10.2967/jnumed.121.262782.
    PubMed     Abstract available


  594. STELLA M, van Rooij R, Lam M, de Jong H, et al
    Lung dose measured on post-radioembolization (90)Y-PET/CT and incidence of radiation pneumonitis.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.263143. doi: 10.2967/jnumed.121.263143.
    PubMed     Abstract available


  595. SHAGERA QA, Artigas C, Karfis I, Critchi G, et al
    (68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.263006. doi: 10.2967/jnumed.121.263006.
    PubMed     Abstract available


  596. MONA CE, Benz MR, Hikmat F, Grogan TR, et al
    Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.262426. doi: 10.2967/jnumed.121.262426.
    PubMed     Abstract available


  597. BRADSHAW TJ, Boellaard R, Dutta J, Jha AK, et al
    Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.262567. doi: 10.2967/jnumed.121.262567.
    PubMed     Abstract available


  598. YOUNIS MH, Lan X, Cai W
    PET with a (68)Ga-labeled FAPI dimer: moving towards theranostics.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.263292. doi: 10.2967/jnumed.121.263292.
    PubMed    


  599. THUILLIER P, Liberini V, Grimaldi S, Rampado O, et al
    Prognostic value of whole-body PET volumetric parameters extracted from (68)Ga-DOTATOC-PET/CT in well-differentiated neuroendocrine tumors.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.262652. doi: 10.2967/jnumed.121.262652.
    PubMed     Abstract available


  600. KESNER AL
    Commercially competitive vendor-agnostic image reconstruction could be a leap forward for PET harmonization.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.263421. doi: 10.2967/jnumed.121.263421.
    PubMed    


  601. NIMMAGADDA S
    Imaging PD-L1 expression in melanoma brain metastases.
    J Nucl Med. 2021 Nov 5. pii: jnumed.121.263209. doi: 10.2967/jnumed.121.263209.
    PubMed    


  602. SCOTT AM, Czernin J
    Perspectives on Theranostics and Nuclear Medicine: A Conversation Between Andrew Scott and Johannes Czernin.
    J Nucl Med. 2021;62:1492-1494.
    PubMed    


  603. CALAIS J, Czernin J
    PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
    J Nucl Med. 2021;62:1489-1491.
    PubMed    


  604. PARKER MFL, Blecha J, Rosenberg O, Ohliger M, et al
    Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2.
    J Nucl Med. 2021;62:1631-1637.
    PubMed     Abstract available


  605. HORSAGER J, Knudsen K, Borghammer P
    Radionuclide Imaging of the Gut-Brain Axis in Parkinson Disease.
    J Nucl Med. 2021;62:1504-1505.
    PubMed    


  606. MILLER RJH, Sharir T, Otaki Y, Gransar H, et al
    Quantitation of Poststress Change in Ventricular Morphology Improves Risk Stratification.
    J Nucl Med. 2021;62:1582-1590.
    PubMed     Abstract available


  607. BAUM RP, Zhang J, Schuchardt C, Muller D, et al
    First-in-Humans Study of the SSTR Antagonist (177)Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.
    J Nucl Med. 2021;62:1571-1581.
    PubMed     Abstract available


  608. PARGHANE RV, Bhandare M, Chaudhari V, Ostwal V, et al
    Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant (177)Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors.
    J Nucl Med. 2021;62:1558-1563.
    PubMed     Abstract available


  609. ZHOU Z, Meshaw R, Zalutsky MR, Vaidyanathan G, et al
    Site-Specific and Residualizing Linker for (18)F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment.
    J Nucl Med. 2021;62:1624-1630.
    PubMed     Abstract available


    October 2021
  610. YUSUFALY T, Zou J, Nelson T, Williamson C, et al
    Improved Prognosis of Treatment Failure in Cervical Cancer with Non-Tumor Positron Emission Tomography / Computed Tomography Radiomics.
    J Nucl Med. 2021 Oct 28. pii: jnumed.121.262618. doi: 10.2967/jnumed.121.262618.
    PubMed     Abstract available


  611. AHLMAN MA, Maass-Moreno R, Grayson PC peter.gray
    Reply LTE, On Semi-quantitative Methods for Assessing Vascular (18)FDG-PET Activity in Large-Vessel Vasculitis.
    J Nucl Med. 2021 Oct 28. pii: jnumed.121.263158. doi: 10.2967/jnumed.121.263158.
    PubMed    


  612. BURGGRAAFF CN, Eertink JJ, Lugtenburg PJ, Hoekstra OS, et al
    (18)F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma: The HOVON-84 study.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262205. doi: 10.2967/jnumed.121.262205.
    PubMed     Abstract available


  613. GHEYSENS O, Belkhir L, Jamar F
    Imaging in Post-COVID Lung Disease (PCLD): does [(18)F]-FDG-PET/CT have the Key?
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.263166. doi: 10.2967/jnumed.121.263166.
    PubMed    


  614. LASNON C, Girault G, Lebtahi R, Ansquer C, et al
    Women Authors in Nuclear Medicine Journals: a Survey from 2014 to 2020.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262773. doi: 10.2967/jnumed.121.262773.
    PubMed     Abstract available


  615. MIYAHIRA AK, Soule HR
    The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Foundational Role of the Prostate Cancer Foundation.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262997. doi: 10.2967/jnumed.121.262997.
    PubMed     Abstract available


  616. SCHMIDKONZ C
    Perspective on Fibroblast Activation Protein Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases: Imaging Fibrosis - a New Paradigm for Molecular Imaging?
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262944. doi: 10.2967/jnumed.121.262944.
    PubMed    


  617. SONNI I, Felker ER, Lenis AT, Sisk AE, et al
    Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial.
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262398. doi: 10.2967/jnumed.121.262398.
    PubMed     Abstract available


  618. LE ROUX PY, Bonnefoy PB, Bahloul A, Denizot B, et al
    Lung scintigraphy for pulmonary embolism diagnosis in COVID-19 patients: a multicenter study.
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262955. doi: 10.2967/jnumed.121.262955.
    PubMed     Abstract available


  619. RISCHKA L, Vraka C, Pichler V, Rasul S, et al
    First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-(11)C-Me-NB1.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262427. doi: 10.2967/jnumed.121.262427.
    PubMed     Abstract available


  620. FERDINANDUS J, Fendler WP, Farolfi A, Washington S, et al
    PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262821. doi: 10.2967/jnumed.121.262821.
    PubMed     Abstract available


  621. KESSLER L, Ferdinandus J, Hirmas N, Zarrad F, et al
    Pitfalls and common findings in (68)Ga-FAPI-PET - A pictorial analysis.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262808. doi: 10.2967/jnumed.121.262808.
    PubMed     Abstract available


  622. MAHAJAN S, Barker CA, Mauguen A, D'Angelo SP, et al
    (18)F-FDG PET/CT for post-treatment surveillance imaging of patients with stage III Merkel cell carcinoma.
    J Nucl Med. 2021 Oct 7. pii: jnumed.121.262882. doi: 10.2967/jnumed.121.262882.
    PubMed     Abstract available


  623. BARATTO L, Hawk KE, States L, Qi J, et al
    PET/MRI Improves Management of Children with Cancer.
    J Nucl Med. 2021;62:1334-1340.
    PubMed     Abstract available


  624. JOHNSON BJ, Van Abel KM, Ma DJ, Johnson DR, et al
    (18)F-FDG-Avid Axillary Lymph Nodes After COVID-19 Vaccination.
    J Nucl Med. 2021;62:1483-1484.
    PubMed    


  625. PARK S, Parihar AS, Bodei L, Hope TA, et al
    Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.
    J Nucl Med. 2021;62:1323-1329.
    PubMed     Abstract available


  626. BERGER DMS, van den Berg NS, van der Noort V, van der Hiel B, et al
    Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region.
    J Nucl Med. 2021;62:1357-1362.
    PubMed     Abstract available


  627. ZHU W, Cheng Y, Jia R, Zhao H, et al
    A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors.
    J Nucl Med. 2021;62:1398-1405.
    PubMed     Abstract available


    September 2021
  628. TAHERPOUR J, Jaber M, Voges B, Apostolova I, et al
    Predicting the outcome of epilepsy surgery by covariance pattern analysis of ictal perfusion SPECT.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262702. doi: 10.2967/jnumed.121.262702.
    PubMed     Abstract available


  629. XU M, Zhang P, Ding J, Chen J, et al
    Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262533. doi: 10.2967/jnumed.121.262533.
    PubMed     Abstract available


  630. PALESTRO C, Clark A, Grady E, Heiba S, et al
    Appropriate Use Criteria for the Use of Nuclear Medicine in Musculoskeletal Infection Imaging.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262579. doi: 10.2967/jnumed.121.262579.
    PubMed    


  631. CROMPTON J, Armstrong WR, Eckardt MA, Seyedroudbari A, et al
    (18)F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262502. doi: 10.2967/jnumed.121.262502.
    PubMed     Abstract available


  632. JADVAR H, Calais J, Fanti S, Feng F, et al
    Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.263262. doi: 10.2967/jnumed.121.263262.
    PubMed    


  633. GU B, Xu X, Zhang J, Ou X, et al
    The Added Value of (68)Ga-FAPI-04 PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG Negative Findings.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262790. doi: 10.2967/jnumed.121.262790.
    PubMed     Abstract available


  634. HU Y, Liu G, Yu H, Wang Y, et al
    Feasibility of ultra-low (18)F-FDG activity acquisitions using total-body PET/CT.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262038. doi: 10.2967/jnumed.121.262038.
    PubMed     Abstract available


  635. ZHAO L, Niu B, Fang J, Pang Y, et al
    Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of (68)Ga-labeled FAPI dimer.
    J Nucl Med. 2021 Sep 23. pii: jnumed.121.263016. doi: 10.2967/jnumed.121.263016.
    PubMed     Abstract available


  636. WEBER M, Schmitz J, Maric I, Pabst KM, et al
    Diagnostic performance of [(124)I]m-iodobenzylguanidine PET/CT in patients with pheochromocytoma.
    J Nucl Med. 2021 Sep 23. pii: jnumed.121.262797. doi: 10.2967/jnumed.121.262797.
    PubMed     Abstract available


  637. SONG H, Iagaru A, Rowe SP
    (18)F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval.
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262989. doi: 10.2967/jnumed.121.262989.
    PubMed     Abstract available


  638. NIENHUIS PH, Antunes IF, Glaudemans AWJM, Jalving M, et al
    (18)F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262368. doi: 10.2967/jnumed.121.262368.
    PubMed     Abstract available


  639. ZANOVELLO M, Soraru G, Campi C, Anglani M, et al
    Brainstem glucose hypermetabolism in ALS/FTD and shorten survival: a (18)F-FDG PET/MR study.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262232. doi: 10.2967/jnumed.121.262232.
    PubMed     Abstract available


  640. MHLANGA J, Haq A, Derenoncourt P, Bhandiwad A, et al
    (18)F-FDG Positron Emission Tomography in Myocardial Viability Assessment: A Practical and Time Efficient Protocol.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262432. doi: 10.2967/jnumed.121.262432.
    PubMed     Abstract available


  641. LAFFON E, Marthan R
    On Semi-quantitative Methods for Assessing Vascular (18)FDG-PET Activity in Large-Vessels Vasculitis.
    J Nucl Med. 2021 Sep 2. pii: jnumed.121.263060. doi: 10.2967/jnumed.121.263060.
    PubMed    


  642. FOURQUET A, Rosenberg A, Mena E, Shih JJ, et al
    A comparison of (18)F-DCFPyL, (18)F-NaF and (18)F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer.
    J Nucl Med. 2021 Sep 2. pii: jnumed.121.262371. doi: 10.2967/jnumed.121.262371.
    PubMed     Abstract available


  643. CARRASQUILLO JA, Chen CC, Jha A, Pacak K, et al
    Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
    J Nucl Med. 2021;62:1192-1199.
    PubMed     Abstract available


  644. CZERNIN J, Radu C, Ribas A
    Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni Ribas.
    J Nucl Med. 2021;62:1178-1180.
    PubMed    


  645. JALLINOJA VIJ, Houghton JL
    Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy.
    J Nucl Med. 2021;62:1200-1206.
    PubMed     Abstract available


    August 2021
  646. SEIFERT R, Sandach P, Kersting D, Fendler WP, et al
    Repeatability of (68)Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
    J Nucl Med. 2021 Aug 26. pii: jnumed.121.262528. doi: 10.2967/jnumed.121.262528.
    PubMed     Abstract available


  647. BAG AK, Wing MN, Sabin ND, Hwang SN, et al
    [(11)C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence.
    J Nucl Med. 2021 Aug 26. pii: jnumed.120.261891. doi: 10.2967/jnumed.120.261891.
    PubMed     Abstract available


  648. IQBAL R, Yaqub M, Oprea-Lager DE, Liu Y, et al
    Biodistribution of (18)F-FES in patients with metastatic ER+ breast cancer undergoing treatment with Rintodestrant (G1T48), a novel selective estrogen receptor degrader.
    J Nucl Med. 2021 Aug 26. pii: jnumed.121.262500. doi: 10.2967/jnumed.121.262500.
    PubMed     Abstract available


  649. LO AC, James LP, Prica A, Raymakers A, et al
    Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262324. doi: 10.2967/jnumed.121.262324.
    PubMed     Abstract available


  650. FARWELL MD, Gamache RF, Babazada H, Hellmann MD, et al
    CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of (89)Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262485. doi: 10.2967/jnumed.121.262485.
    PubMed     Abstract available


  651. PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
    Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
    PubMed     Abstract available


  652. PAQUETTE M, Espinosa-Bentancourt E, Lavallee E, Phoenix S, et al
    (18)F-4FMFES and (18)F-FDG PET/CT in ER+ endometrial carcinomas: preliminary report.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262617. doi: 10.2967/jnumed.121.262617.
    PubMed     Abstract available


  653. MATHEY C, Keyzer C, Blocklet D, Van Simaeys G, et al
    (18)F-fluorocholine PET/CT is more sensitive than (11)C-methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262395. doi: 10.2967/jnumed.121.262395.
    PubMed     Abstract available


  654. SMIT J, Borm FJ, Niemeijer AN, Huisman MC, et al
    PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262473. doi: 10.2967/jnumed.121.262473.
    PubMed     Abstract available


  655. HOFMAN MS
    Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262890. doi: 10.2967/jnumed.121.262890.
    PubMed    


  656. LANGBEIN T, Wurzer A, Gafita A, Robertson A, et al
    The Influence of Specific Activity on the Biodistribution of (18)F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262471. doi: 10.2967/jnumed.121.262471.
    PubMed     Abstract available


  657. LU P, Benabdallah N, Jiang W, Simons BW, et al
    Blind Image Restoration Enhances Digital Autoradiographic Imaging of Radiopharmaceutical Tissue Distribution.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262270. doi: 10.2967/jnumed.121.262270.
    PubMed     Abstract available


  658. NAGANAWA M, Nabulsi NB, Matuskey D, Henry S, et al
    Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer (11)C-TASP699.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262430. doi: 10.2967/jnumed.121.262430.
    PubMed     Abstract available


  659. FENG T, Wu Y, Zhao Y, Xu T, et al
    Whole-body Parametric Imaging of FDG PET using uEXPLORER with Reduced Scan Time.
    J Nucl Med. 2021 Aug 12. pii: jnumed.120.261651. doi: 10.2967/jnumed.120.261651.
    PubMed     Abstract available


  660. BRAGINA O, Chernov V, Schulga A, Konovalova E, et al
    Phase I trial of (99m)Tc-(HE)3-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262542. doi: 10.2967/jnumed.121.262542.
    PubMed     Abstract available


  661. STABIN MG, Wendt RE 3rd, Flux GD
    RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals Part 1. Collection of Data for Radiopharmaceutical Dosimetry.
    J Nucl Med. 2021 Aug 5. pii: jnumed.120.259200. doi: 10.2967/jnumed.120.259200.
    PubMed     Abstract available


  662. STABIN MG, Wendt RE 3rd, Flux GD
    RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals Part 2. Data Analysis and Dosimetry.
    J Nucl Med. 2021 Aug 5. pii: jnumed.121.262034. doi: 10.2967/jnumed.121.262034.
    PubMed     Abstract available


  663. BRENDLE C, Maier C, Bender B, Schittenhelm J, et al
    Impact of (18)F-FET PET/MR on clinical management of brain tumor patients.
    J Nucl Med. 2021 Aug 5. pii: jnumed.121.262051. doi: 10.2967/jnumed.121.262051.
    PubMed     Abstract available


  664. IAGARU A
    2021 SNMMI Highlights Lecture: General Nuclear Medicine.
    J Nucl Med. 2021;62:12N-17N.
    PubMed    



  665. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    PubMed    



  666. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    PubMed    


  667. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021;62:1025-1026.
    PubMed    


  668. CARRASQUILLO JA, Chen CC, Jha A, Ling A, et al
    Imaging of Pheochromocytoma and Paraganglioma.
    J Nucl Med. 2021;62:1033-1042.
    PubMed     Abstract available


  669. HOFMAN MS, Calais J, Czernin J
    Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jeremie Calais.
    J Nucl Med. 2021;62:1027-1030.
    PubMed    


  670. WAHL RL, Dilsizian V, Palestro CJ
    At Last, (18)F-FDG for Inflammation and Infection!
    J Nucl Med. 2021;62:1048-1049.
    PubMed    


  671. CLEMENTE GS, Antunes IF, Kurhade S, van den Berg MPM, et al
    Mapping Arginase Expression with (18)F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary alpha-Amino Acids.
    J Nucl Med. 2021;62:1163-1170.
    PubMed     Abstract available


  672. FERNANDEZ R, Eppard E, Lehnert W, Jimenez-Franco LD, et al
    Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases.
    J Nucl Med. 2021;62:1126-1132.
    PubMed     Abstract available


  673. LASSEN ML, Otaki Y, Kavanagh P, Miller RJH, et al
    Simulation of Low-Dose Protocols for Myocardial Perfusion (82)Rb Imaging.
    J Nucl Med. 2021;62:1112-1117.
    PubMed     Abstract available


  674. URBAN S, Meyer C, Dahlbom M, Farkas I, et al
    Radiation Dosimetry of (99m)Tc-PSMA I&S: A Single-Center Prospective Study.
    J Nucl Med. 2021;62:1075-1081.
    PubMed     Abstract available


    July 2021
  675. DIETLEIN F, Kobe C, Munoz Vazquez S, Fischer T, et al
    An (89)Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262290. doi: 10.2967/jnumed.121.262290.
    PubMed     Abstract available


  676. DONG L, Su Y, Zhu Y, Markowski MC, et al
    The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262411. doi: 10.2967/jnumed.121.262411.
    PubMed     Abstract available


  677. ABGHARI-GERST M, Armstrong WR, Nguyen K, Calais J, et al
    A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262412. doi: 10.2967/jnumed.121.262412.
    PubMed     Abstract available


  678. ZHOU X, Jiang J, Yang X, Liu T, et al
    First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262045. doi: 10.2967/jnumed.121.262045.
    PubMed     Abstract available


  679. PATHMANANDAVEL S, Crumbaker M, Yam AO, Nguyen A, et al
    (177)Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262552. doi: 10.2967/jnumed.121.262552.
    PubMed     Abstract available


  680. WOFF E, Salvatore L, Marmorino F, Genovesi D, et al
    Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.
    J Nucl Med. 2021 Jul 29. pii: jnumed.120.245357. doi: 10.2967/jnumed.120.245357.
    PubMed     Abstract available


  681. CATANA C, Laforest R, An H, Boada F, et al
    A Path to Qualification of PET/MR Scanners for Multicenter Brain Imaging Studies: Evaluation of MR-based Attenuation Correction Methods Using a Patient Phantom.
    J Nucl Med. 2021 Jul 22. pii: jnumed.120.261881. doi: 10.2967/jnumed.120.261881.
    PubMed     Abstract available


  682. PRENOSIL GA, Sari H, Furstner M, Afshar-Oromieh A, et al
    Performance Characteristics of the Biograph Vision Quadra PET/CT system with long axial field of view using the NEMA NU 2-2018 Standard.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.261972. doi: 10.2967/jnumed.121.261972.
    PubMed     Abstract available


  683. OREVI M, Chicheportiche A, Ben-Haim S
    Lessons learned from post-COVID-19 vaccination PET/CT studies.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.262348. doi: 10.2967/jnumed.121.262348.
    PubMed     Abstract available


  684. GANS D, Braet P, Ahmadi Bidakhvidi N, Deroose CM, et al
    (18)F-FDG PET-CT sheds a Light on a Case of Hyponatremia.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.262369. doi: 10.2967/jnumed.121.262369.
    PubMed     Abstract available


  685. VONKEN EPA, Bruijnen RCG, Snijders TJ, Seute T, et al
    Intra-arterial administration boosts (177)Lu-HA-DOTATATE accumulation in salvage meningioma patients.
    J Nucl Med. 2021 Jul 22. pii: jnumed.121.262491. doi: 10.2967/jnumed.121.262491.
    PubMed     Abstract available


  686. ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
    Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
    PubMed     Abstract available


  687. SANCHEZ-CATASUS C, Bohnen NI, D'Cruz N, Muller M, et al
    Striatal acetylcholine-dopamine imbalance in Parkinson's disease: in vivo neuroimaging study with dual-tracer PET and dopaminergic PET-informed correlational tractography.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261939. doi: 10.2967/jnumed.121.261939.
    PubMed     Abstract available


  688. IMPERIALE A, Boursier C, Sahakian N, Ouvrard E, et al
    Values of (68)Ga-DOTATOC and Carbidopa-assisted (18)F-DOPA PET/CT for insulinoma localization.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.262401. doi: 10.2967/jnumed.121.262401.
    PubMed     Abstract available


  689. THORNTON A, Fraioli F, Wan S, Garthwaite HS, et al
    Evolution of (18)F-FDG-PET/CT findings in patients following COVID-19 pneumonia: An Initial Investigation.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.262296. doi: 10.2967/jnumed.121.262296.
    PubMed     Abstract available


  690. BENZ MR, Armstrong WR, Ceci F, Polverari G, et al
    (18)F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261952. doi: 10.2967/jnumed.121.261952.
    PubMed     Abstract available


  691. NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
    First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
    PubMed     Abstract available


  692. READER AJ, Schramm G
    AI for PET image reconstruction.
    J Nucl Med. 2021 Jul 8. pii: jnumed.121.262303. doi: 10.2967/jnumed.121.262303.
    PubMed    


  693. IM C, Kim H, Zaheer J, Kim JY, et al
    PET tracing of biodistribution for orally administered (64)Cu-labeled polystyrene in mice.
    J Nucl Med. 2021 Jul 2. pii: jnumed.120.256982. doi: 10.2967/jnumed.120.256982.
    PubMed     Abstract available


  694. BOSS M, Rottenburger C, Brenner W, Blankenstein O, et al
    (68)Ga-NODAGA-exendin-4 PET improves the detection of focal congenital hyperinsulinism.
    J Nucl Med. 2021 Jul 2. pii: jnumed.121.262327. doi: 10.2967/jnumed.121.262327.
    PubMed     Abstract available


  695. CERCI JJ, Fanti S, Lobato EE, Kunikowska J, et al
    Diagnostic performance and clinical impact of (68)Ga-PSMA-11 imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study).
    J Nucl Med. 2021 Jul 2. pii: jnumed.120.261886. doi: 10.2967/jnumed.120.261886.
    PubMed     Abstract available


  696. STATES LJ, Davis JC, Hamel SM, Becker SA, et al
    (18)F-6-Fluoro-l-Dopa PET/CT Imaging of Congenital Hyperinsulinism.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  697. WAHL R
    Nuclear Medicine Innovations: Providing Access for All.
    J Nucl Med. 2021;62:16N.
    PubMed    


  698. MARZELLA L, Czernin J, Hope T
    Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope.
    J Nucl Med. 2021;62:881-883.
    PubMed    


  699. BLAZHENETS G, Schroeter N, Bormann T, Thurow J, et al
    Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients.
    J Nucl Med. 2021;62:910-915.
    PubMed     Abstract available


  700. WILD D, Antwi K, Fani M, Christ ER, et al
    Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  701. HINDIE E, Schwartz P, Avram AM, Imperiale A, et al
    Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  702. CRANDALL JP, Wahl RL
    Perspectives on Brown Adipose Tissue Imaging: Insights from Preclinical and Clinical Observations from the Last and Current Century.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  703. SUNDIN A, Hindie E, Avram AM, Tabarin A, et al
    A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


    June 2021
  704. BARCA C, Kiliaan AJ, Foray C, Wachsmuth L, et al
    A longitudinal PET/MR imaging study of colony stimulating factor-1 receptor-mediated microglia depletion in experimental stroke.
    J Nucl Med. 2021 Jun 24. pii: jnumed.121.262279. doi: 10.2967/jnumed.121.262279.
    PubMed     Abstract available


  705. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021 Jun 24. pii: jnumed.121.262710. doi: 10.2967/jnumed.121.262710.
    PubMed    


  706. MEIER SR, Sehlin D, Roshanbin S, Lim Falk V, et al
    (11)C-PIB and (124)I-antibody PET provide differing estimates of brain amyloid-beta after therapeutic intervention.
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262083. doi: 10.2967/jnumed.121.262083.
    PubMed     Abstract available


  707. WAKFIE-CORIEH CG, Ferrando-Castagnetto F, Blanes Garcia AM, Garcia-Esquinas MG, et al
    Incidental findings suggestive of COVID-19 pneumonia in oncological patients undergoing 18F-FDG PET/CT studies: association between metabolic and structural lung changes.
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.261915. doi: 10.2967/jnumed.121.261915.
    PubMed     Abstract available


  708. ZHANG X, Landgraf L, Bailis N, Unger M, et al
    Image-guided High-Intensity Focused Ultrasound, A Novel Application for Interventional Nuclear Medicine?
    J Nucl Med. 2021 Jun 4. pii: jnumed.120.256230. doi: 10.2967/jnumed.120.256230.
    PubMed     Abstract available


  709. DASHORA HR, Rosenblum JS, Quinn KA, Alessi H, et al
    Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262326. doi: 10.2967/jnumed.121.262326.
    PubMed     Abstract available


  710. MIX M, Renaud T, Kind F, Nemer U, et al
    Kidney doses in (177)Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262245. doi: 10.2967/jnumed.121.262245.
    PubMed     Abstract available


  711. ORELLANA P, Mut F, Estrada E, Lette MM, et al
    Status of Nuclear Medicine in Latin America and the Caribbean: IAEA Analysis of Development in the Past 6 Years.
    J Nucl Med. 2021;62:23N-29N.
    PubMed    


  712. ALLIS J, Mankoff D
    Industry Perspective on the Changing Nuclear Medicine Landscape: A Conversation Between Jonathan Allis and David Mankoff.
    J Nucl Med. 2021;62:749-751.
    PubMed    


  713. GAN HK, Burge M, Solomon B, Lee ST, et al
    A Phase 1 and Biodistribution Study of ABT-806i, an (111)In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
    J Nucl Med. 2021;62:787-794.
    PubMed     Abstract available


  714. EBBERS SC, Barentsz MW, de Keizer B, Krijger GC, et al
    A Rapid and Safe Infusion Protocol for (177)Lu Peptide Receptor Radionuclide Therapy.
    J Nucl Med. 2021;62:816-822.
    PubMed     Abstract available


  715. ERIKSSON O, Velikyan I, Haack T, Bossart M, et al
    Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.
    J Nucl Med. 2021;62:833-838.
    PubMed     Abstract available


    May 2021
  716. GAFITA A, Wang H, Robertson A, Armstrong WR, et al
    Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
    J Nucl Med. 2021 May 28. pii: jnumed.121.261906. doi: 10.2967/jnumed.121.261906.
    PubMed     Abstract available


  717. RAMAN F, Fang YD, Grandhi S, Murchison CF, et al
    Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures.
    J Nucl Med. 2021 May 28. pii: jnumed.120.254490. doi: 10.2967/jnumed.120.254490.
    PubMed     Abstract available


  718. JIN X, Wei M, Wang S, Wang G, et al
    Detecting fibroblast activation proteins in lymphoma using (68)Ga-FAPI PET/CT.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262134. doi: 10.2967/jnumed.121.262134.
    PubMed     Abstract available


  719. JACENE HA, Liu M, Cheng SC, Abbott A, et al
    Imaging Androgen Receptors in Breast Cancer with (18)F-fluoro-5alpha-dihydrotestosterone-PET: A Pilot Study.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262068. doi: 10.2967/jnumed.121.262068.
    PubMed     Abstract available


  720. SEBAN RD, Champion L, Muneer I, Synn S, et al
    Potential theranostic role of bone marrow glucose metabolism on baseline [18F]-FDG PET/CT in metastatic melanoma.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262361. doi: 10.2967/jnumed.121.262361.
    PubMed    


  721. KRAUS S, Dierks A, Rasche L, Kertels O, et al
    (68)Ga-Pentixafor-PET/CT imaging represents a novel approach to detect chemokine receptor CXCR4 expression in myeloproliferative neoplasms.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262206. doi: 10.2967/jnumed.121.262206.
    PubMed     Abstract available


  722. MUNOZ C, Ellis S, Nekolla SG, Kunze KP, et al
    MR-guided motion-corrected PET image reconstruction for cardiac PET-MR.
    J Nucl Med. 2021 May 28. pii: jnumed.120.254235. doi: 10.2967/jnumed.120.254235.
    PubMed     Abstract available


  723. NICKOLS N, Anand A, Johnsson K, Brynolfsson J, et al
    aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.
    J Nucl Med. 2021 May 28. pii: jnumed.120.261863. doi: 10.2967/jnumed.120.261863.
    PubMed     Abstract available


  724. BIECHELE G, Sebastian Monasor L, Wind K, Blume T, et al
    Glitter in the Darkness? Non-fibrillar beta-amyloid Plaque Components Significantly Impact the beta-amyloid PET Signal in Mouse Models of Alzheimer's Disease.
    J Nucl Med. 2021 May 20. pii: jnumed.120.261858. doi: 10.2967/jnumed.120.261858.
    PubMed     Abstract available


  725. ZARAGORI T, Oster J, Roch V, Hossu G, et al
    (18)F-FDOPA PET for the non-invasive prediction of glioma molecular parameters: a radiomics study.
    J Nucl Med. 2021 May 20. pii: jnumed.120.261545. doi: 10.2967/jnumed.120.261545.
    PubMed     Abstract available


  726. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
    PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
    J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
    PubMed     Abstract available


  727. MORAWITZ J, Bruckmann NM, Dietzel F, Ullrich T, et al
    Determining the axillary nodal status with four current imaging modalities including (18)F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standard.
    J Nucl Med. 2021 May 20. pii: jnumed.121.262009. doi: 10.2967/jnumed.121.262009.
    PubMed     Abstract available


  728. COLLET S, Guillamo JS, Berro DH, Chakhoyan A, et al
    Simultaneous mapping of vasculature, hypoxia and proliferation using DSC-MRI, (18)F-FMISO PET, and (18)F-FLT PET in relation to contrast enhancement in newly diagnosed glioblastoma.
    J Nucl Med. 2021 May 20. pii: jnumed.120.249524. doi: 10.2967/jnumed.120.249524.
    PubMed     Abstract available


  729. BARBATO F, Fendler WP, Rauscher I, Herrmann K, et al
    PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
    J Nucl Med. 2021 May 14. pii: jnumed.121.262120. doi: 10.2967/jnumed.121.262120.
    PubMed     Abstract available


  730. EL-ATOUM B, Ebert M, Bucher B, Afify Z, et al
    Is (18)F-FDG PET/CT effective in identifying true residual disease after treatment of pediatric PTLD?
    J Nucl Med. 2021 May 14. pii: jnumed.121.262414. doi: 10.2967/jnumed.121.262414.
    PubMed    


  731. BOERS J, Loudini N, Brunsch CL, Koza SA, et al
    Value of (18)F-FES-PET to solve clinical dilemmas in breast cancer patients: a retrospective study.
    J Nucl Med. 2021 May 14. pii: jnumed.120.256826. doi: 10.2967/jnumed.120.256826.
    PubMed     Abstract available


  732. HENDERSON TA, DeBruin S, Briandet P
    (18)F-FDG PET National Coverage Determination for Infection/Inflammation Retired.
    J Nucl Med. 2021;62:18N-22N.
    PubMed    


  733. WAHL RL, Ahuja S, Clarke B
    Current Landscape of Radiopharmaceutical Therapies: SNMMI Therapy Task Force Survey.
    J Nucl Med. 2021;62:11N-16N.
    PubMed    



  734. Challenges and Promise for Nuclear Medicine in Africa: A Conversation Between Mike Sathekge and Johannes Czernin.
    J Nucl Med. 2021;62:593-595.
    PubMed    


  735. YOSHINAGA K, Abe T, Okamoto S, Uchiyama Y, et al
    Effects of Repeated (131)I-Meta-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors.
    J Nucl Med. 2021;62:685-694.
    PubMed     Abstract available


  736. NAZERI A, Crandall JP, Fraum TJ, Wahl RL, et al
    Repeatability of Radiomic Features of Brown Adipose Tissue.
    J Nucl Med. 2021;62:700-706.
    PubMed     Abstract available


  737. FENG T, Zhao Y, Shi H, Li H, et al
    Total-Body Quantitative Parametric Imaging of Early Kinetics of (18)F-FDG.
    J Nucl Med. 2021;62:738-744.
    PubMed     Abstract available


  738. SCHAEFER WM, Knollmann D, Meyer PT
    Q/V-SPECT CT in times of COVID-19: Changing the order to improve safety without sacrificing accuracy.
    J Nucl Med. 2021 May 7. pii: jnumed.120.261263. doi: 10.2967/jnumed.120.261263.
    PubMed    


    April 2021
  739. KESSLER L, Ferdinandus J, Hirmas N, Bauer S, et al
    Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial.
    J Nucl Med. 2021 Apr 30. pii: jnumed.121.262096. doi: 10.2967/jnumed.121.262096.
    PubMed     Abstract available


  740. COHEN AS, Grudzinski J, Smith GT, Peterson TE, et al
    First-in-human PET imaging and estimated radiation dosimetry of L-[5-(11)C]-glutamine in patients with metastatic colorectal cancer.
    J Nucl Med. 2021 Apr 30. pii: jnumed.120.261594. doi: 10.2967/jnumed.120.261594.
    PubMed     Abstract available


  741. CHENG JL, Dibble EH, Baird GL, Gordon LL, et al
    Diversity, Equity, and Inclusion in Academic Nuclear Medicine: National Survey of Nuclear Medicine Residency Program Directors.
    J Nucl Med. 2021 Apr 23. pii: jnumed.120.260711. doi: 10.2967/jnumed.120.260711.
    PubMed     Abstract available


  742. KWIECINSKI J, Tzolos E, Meah M, Cadet S, et al
    Machine-learning with (18)F-sodium fluoride PET and quantitative plaque analysis on CT angiography for the future risk of myocardial infarction.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262283. doi: 10.2967/jnumed.121.262283.
    PubMed     Abstract available


  743. FENDLER WP, Herrmann K, Eiber M
    Nuclear Medicine beyond VISION.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262441. doi: 10.2967/jnumed.121.262441.
    PubMed    


  744. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
    PubMed     Abstract available


  745. EIFER M, Tau N, Alhoubani Y, Kanana N, et al
    Covid-19 mRNA Vaccination: Age and Immune Status and its Association with Axillary Lymph Node PET/CT Uptake.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262194. doi: 10.2967/jnumed.121.262194.
    PubMed     Abstract available


  746. GHZALLY Y, Imanli H, Smith M, Mahat J, et al
    Metabolic Scar Assessment with (18)F-FDG -PET: Correlation to Ischemic VT Substrate and Successful Ablation Sites.
    J Nucl Med. 2021 Apr 23. pii: jnumed.120.246413. doi: 10.2967/jnumed.120.246413.
    PubMed     Abstract available


  747. GOGOLA A, Minhas DS, Villemagne VL, Cohen AD, et al
    Direct comparison of the tau PET tracers [(18)F]flortaucipir and [(18)F]MK-6240 in human subjects.
    J Nucl Med. 2021 Apr 16. pii: jnumed.120.254961. doi: 10.2967/jnumed.120.254961.
    PubMed     Abstract available


  748. YOUNG AJ, Pantel AR, Viswanath V, Dominguez TL, et al
    Kinetic and static analysis of poly-(adenosine diphosphate-ribose) polymerase-1 (PARP-1) targeted (18)F-FluorThanatrace ((18)F-FTT) PET images of ovarian cancer.
    J Nucl Med. 2021 Apr 16. pii: jnumed.121.261894. doi: 10.2967/jnumed.121.261894.
    PubMed     Abstract available


  749. QIN C, Shao F, Gai Y, Liu Q, et al
    (68)Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with (18)F-FDG PET/CT.
    J Nucl Med. 2021 Apr 16. pii: jnumed.120.258467. doi: 10.2967/jnumed.120.258467.
    PubMed     Abstract available


  750. LUKEY PT, Wilson FJ
    Quantification of the alphavbeta6 Integrin by PET/CT Imaging in the Lungs of Patients after SARS-CoV2 Infection and Comparison to Fibrotic Lungs.
    J Nucl Med. 2021 Apr 9. pii: jnumed.121.262342. doi: 10.2967/jnumed.121.262342.
    PubMed    


  751. GUGLIELMETTI C, Levi J, Huynh TL, Tiret B, et al
    Longitudinal imaging of T-cells and inflammatory demyelination in a preclinical model of multiple sclerosis using (18)F-FAraG PET and MRI.
    J Nucl Med. 2021 Apr 9. pii: jnumed.120.259325. doi: 10.2967/jnumed.120.259325.
    PubMed     Abstract available


  752. KUO HT, Lin KS, Zhang Z, Uribe CF, et al
    (177)Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
    J Nucl Med. 2021;62:521-527.
    PubMed     Abstract available


    March 2021
  753. ALSULTAN AA, van Roekel C, Barentsz MW, Smits MLJ, et al
    Dose-response and dose-toxicity relationships for yttrium-90 glass radioembolization in patients with colorectal cancer liver metastases.
    J Nucl Med. 2021 Mar 19. pii: jnumed.120.255745. doi: 10.2967/jnumed.120.255745.
    PubMed     Abstract available


  754. WU H, Czernin J
    A Conversation Between Hong Wu and Johannes Czernin.
    J Nucl Med. 2021;62:293-295.
    PubMed    


  755. LODGE MA
    Phantom Preparation Using a Dilution Technique.
    J Nucl Med. 2021;62:303.
    PubMed    


  756. ALBRECHT J, Exner S, Grotzinger C, Prasad S, et al
    Multimodal Imaging of 2-Cycle PRRT with (177)Lu-DOTA-JR11 and (177)Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model.
    J Nucl Med. 2021;62:393-398.
    PubMed     Abstract available


  757. BARRINGTON SF, Zwezerijnen BGJC, de Vet HCW, Heymans MW, et al
    Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium.
    J Nucl Med. 2021;62:332-337.
    PubMed     Abstract available


  758. PEREIRA PMR, Norfleet J, Lewis JS, Escorcia FE, et al
    Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition.
    J Nucl Med. 2021;62:366-371.
    PubMed     Abstract available


    February 2021
  759. SUH M, Im HJ, Ryoo HG, Kang KW, et al
    Head to head comparison of (68)Ga-NGUL and (68)Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study.
    J Nucl Med. 2021 Feb 26. pii: jnumed.120.258434. doi: 10.2967/jnumed.120.258434.
    PubMed     Abstract available


  760. SARTOR O, Hope TA, Calais J, Fendler WP, et al
    Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.
    J Nucl Med. 2021;62:146-148.
    PubMed    


  761. CARLUCCI G, Ippisch R, Slavik R, Mishoe A, et al
    (68)Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership.
    J Nucl Med. 2021;62:149-155.
    PubMed     Abstract available


  762. ZANOTTI-FREGONARA P, Lammertsma AA, Innis RB
    (11)C Dosimetry Scans Should Be Abandoned.
    J Nucl Med. 2021;62:158-159.
    PubMed    


  763. ALTMANN A, Haberkorn U, Siveke J
    The Latest Developments in Imaging of Fibroblast Activation Protein.
    J Nucl Med. 2021;62:160-167.
    PubMed     Abstract available


  764. SLOMKA PJ, Moody JB, Miller RJH, Renaud JM, et al
    Quantitative clinical nuclear cardiology, part 2: Evolving/emerging applications.
    J Nucl Med. 2021;62:168-176.
    PubMed     Abstract available


  765. AHMED H, Wallimann R, Haider A, Hosseini V, et al
    Preclinical Development of (18)F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis.
    J Nucl Med. 2021;62:259-265.
    PubMed     Abstract available


  766. HADDAD J, Latoche JD, Nigam S, Bellavia MC, et al
    Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
    J Nucl Med. 2021;62:280-286.
    PubMed     Abstract available


    January 2021
  767. ARMSTRONG WR, Gafita A, Zhu S, Thin P, et al
    The impact of monosodium glutamate on (68)Ga-PSMA-11 biodistribution in men with prostate cancer: a prospective randomized, controlled, imaging study.
    J Nucl Med. 2021 Jan 28. pii: jnumed.120.257931. doi: 10.2967/jnumed.120.257931.
    PubMed     Abstract available


  768. BODAR YJL, Koene BPF, Jansen BHE, Cysouw MCF, et al
    Standardized Uptake Values are Adequate Measures of Lesional (18)F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
    J Nucl Med. 2021 Jan 28. pii: jnumed.120.260232. doi: 10.2967/jnumed.120.260232.
    PubMed     Abstract available


  769. LAFFON E, Marthan R
    Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
    J Nucl Med. 2021;62:144.
    PubMed    


  770. BUVAT I, Herrmann K, Stremitzer A, Tobia K, et al
    Irene Buvat and Ken Herrmann Talk with Alexander Stremitzer, Kevin Tobia, and Aileen Nielsen.
    J Nucl Med. 2021;62:3-5.
    PubMed    


  771. PRICE WN 2ND, Gerke S, Cohen IG
    How Much Can Potential Jurors Tell Us About Liability for Medical Artificial Intelligence?
    J Nucl Med. 2021;62:15-16.
    PubMed    


  772. TOBIA K, Nielsen A, Stremitzer A
    When Does Physician Use of AI Increase Liability?
    J Nucl Med. 2021;62:17-21.
    PubMed     Abstract available


  773. CAPOBIANCO N, Meignan M, Cottereau AS, Vercellino L, et al
    Deep-Learning (18)F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma.
    J Nucl Med. 2021;62:30-36.
    PubMed     Abstract available


  774. ZIESSMAN HA, Jeyasingam M, Khan AU, McMahan Z, et al
    Experience with Esophagogastrointestinal Transit Scintigraphy in the Initial 229 Patients: Multiple Regions of Dysmotility Are Common.
    J Nucl Med. 2021;62:115-122.
    PubMed     Abstract available


    November 2020
  775. AYATI N, Lee ST, Zakavi SR, Cheng M, et al
    Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.254508. doi: 10.2967/jnumed.120.254508.
    PubMed     Abstract available


    October 2020
  776. VIDAL-SICART S, Rioja ME, Prieto A, Goni E, et al
    Sentinel Lymph Node Biopsy in breast cancer with (99m)Tc-Tilmanocept: A novel tracer in the real life. A multicenter study.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.252064. doi: 10.2967/jnumed.120.252064.
    PubMed     Abstract available


    August 2020
  777. MACASKILL MG, Stadulyte A, Williams L, Morgan TEF, et al
    Quantification of macrophage-driven inflammation during myocardial infarction with (18)F-LW223, a novel TSPO radiotracer with binding independent of the rs6971 human polymorphism.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.243600. doi: 10.2967/jnumed.120.243600.
    PubMed     Abstract available


  778. KUMAR M, Salem K, Jeffery JJ, Yan Y, et al
    Longitudinal molecular imaging of progesterone receptor reveals early differential response to endocrine therapy in breast cancer with an activating ESR1 mutation.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.249508. doi: 10.2967/jnumed.120.249508.
    PubMed     Abstract available


  779. NICOLAY NH, Ruhle A, Wiedenmann N, Niedermann G, et al
    Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer - Results from a Prospective Imaging Trial.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.248633. doi: 10.2967/jnumed.120.248633.
    PubMed     Abstract available


  780. BRAGINA O, von Witting E, Garousi J, Zelchan R, et al
    Phase I study of (99m)Tc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer.
    J Nucl Med. 2020 Aug 17. pii: jnumed.120.248799. doi: 10.2967/jnumed.120.248799.
    PubMed     Abstract available


    June 2020
  781. VAN ROEKEL C, Bastiaannet R, Smits MLJ, Bruijnen RC, et al
    Dose-effect relationships of holmium-166 radioembolization in colorectal cancer.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.243832. doi: 10.2967/jnumed.120.243832.
    PubMed     Abstract available


    May 2020
  782. HARSINI S, Saprunoff H, Alden TM, Mohammadi B, et al
    The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
    J Nucl Med. 2020 May 8. pii: jnumed.120.246983. doi: 10.2967/jnumed.120.246983.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Nuclear Medicine is free of charge.